<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="other">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">NPWm4DjHtDfGV5RpqqRD5Bf</article-id>
      <article-id pub-id-type="other">00019</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011001500019</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09700619</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011001500019</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Atualiza&#231;&#227;o Cl&#237;nica</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Angiog&#234;nese coronariana como resposta end&#243;gena da isquemia mioc&#225;rdica no adulto</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lorier</surname>
            <given-names>Gabriel</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Touri&#241;o</surname>
            <given-names>Cristina</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kalil</surname>
            <given-names>Renato A. K</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">Rio Grande do Sul</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de Ci&#234;ncias da Sa&#250;de de Porto Alegre</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Montevideo</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Universidad de la Rep&#250;blica</institution>
        <country country="UY">Uruguay</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">Rio Grande do Sul</named-content>
        </addr-line>
        <institution content-type="orgname">Funda&#231;&#227;o Universit&#225;ria de Cardiologia</institution>
        <institution content-type="orgdiv1">Instituto de Cardiologia do Rio Grande do Sul </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>12</month>
        <year>2011</year>
      </pub-date>
      <volume>97</volume>
      <issue>6</issue>
      <fpage>e140</fpage>
      <lpage>e148</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>03</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>07</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>13</day>
          <month>06</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>O processo de angiog&#234;nese envolve uma sequ&#234;ncia complexa de est&#237;mulos e respostas integradas, como estimula&#231;&#227;o das c&#233;lulas endoteliais (CE) para sua prolifera&#231;&#227;o e migra&#231;&#227;o, estimula&#231;&#227;o da matriz extracelular, para atra&#231;&#227;o de pericitos e macr&#243;fagos, estimula&#231;&#227;o das c&#233;lulas musculares lisas, para sua prolifera&#231;&#227;o e migra&#231;&#227;o, e forma&#231;&#227;o de novas estruturas vasculares. Angiog&#234;nese &#233; principalmente uma resposta adaptativa &#224; hip&#243;xia tecidual e depende do ac&#250;mulo do fator de crescimento induzido pela hip&#243;xia (FIH-1 &#945;) na zona do mioc&#225;rdio isqu&#234;mico, que serve para aumentar a transcri&#231;&#227;o do fator de crescimento endotelial vascular (VEGF) e seus receptores VEGF-R, pelas CE em sofrimento isqu&#234;mico. Esses passos envolvem mecanismos enzim&#225;ticos e proteases ativadoras do plasminog&#234;nio, metaloproteinases (MMP) da matriz extracelular (MEC) e cinases que provocam a degrada&#231;&#227;o molecular proteol&#237;tica da MEC, bem como pela ativa&#231;&#227;o e a libera&#231;&#227;o de fatores de crescimento, tais como: fator b&#225;sico de crescimento dos fibroblastos (FCFb), VEGF e fator de crescimento insul&#237;nico-1 (FCI-1). Posteriormente, vem a fase intermedi&#225;ria de estabiliza&#231;&#227;o do novo broto neovascular imaturo e a fase final de matura&#231;&#227;o vascular da angiog&#234;nese fisiol&#243;gica. Como conclus&#245;es generaliz&#225;veis, &#233; poss&#237;vel afirmar que a angiog&#234;nese coron&#225;ria em adultos &#233;, fundamentalmente, uma resposta par&#225;crina da rede capilar preexistente em condi&#231;&#245;es fisiopatol&#243;gicas de isquemia e inflama&#231;&#227;o.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Isquemia mioc&#225;rdica</kwd>
        <kwd>neovasculariza&#231;&#227;o fisiol&#243;gica</kwd>
        <kwd>c&#233;lulas endoteliais</kwd>
        <kwd>adulto</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>16</day>
        <month>01</month>
        <year>2012</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ATUALIZA&#199;&#195;O CL&#205;NICA</bold>
    </p>
    <p>
      <bold>Angiog&#234;nese coronariana como resposta end&#243;gena da isquemia mioc&#225;rdica no adulto</bold>
    </p>
    <p>
      <bold>Gabriel Lorier<sup>I</sup>; Cristina Touri&#241;o<sup>I</sup>; Renato A. K. Kalil<sup>II,III</sup></bold>
    </p>
    <p><sup>I</sup>Universidad de La Republica, Montevideo, Uruguay (UDELAR); Porto Alegre, Rio Grande do Sul, Brasil </p>
    <p><sup>II</sup>Instituto de Cardiologia do Rio Grande do Sul - Funda&#231;&#227;o Universit&#225;ria de Cardiologia - (IC/FUC); Porto Alegre, Rio Grande do Sul, Brasil </p>
    <p><sup>III</sup>Universidade Federal de Ci&#234;ncias da Sa&#250;de de Porto Alegre - (UFCSPA), Porto Alegre, Rio Grande do Sul, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>O processo de angiog&#234;nese envolve uma sequ&#234;ncia complexa de est&#237;mulos e respostas integradas, como estimula&#231;&#227;o das c&#233;lulas endoteliais (CE) para sua prolifera&#231;&#227;o e migra&#231;&#227;o, estimula&#231;&#227;o da matriz extracelular, para atra&#231;&#227;o de pericitos e macr&#243;fagos, estimula&#231;&#227;o das c&#233;lulas musculares lisas, para sua prolifera&#231;&#227;o e migra&#231;&#227;o, e forma&#231;&#227;o de novas estruturas vasculares. </p>
    <p> Angiog&#234;nese &#233; principalmente uma resposta adaptativa &#224; hip&#243;xia tecidual e depende do ac&#250;mulo do fator de crescimento induzido pela hip&#243;xia (FIH-1 &#945;) na zona do mioc&#225;rdio isqu&#234;mico, que serve para aumentar a transcri&#231;&#227;o do fator de crescimento endotelial vascular (VEGF) e seus receptores VEGF-R, pelas CE em sofrimento isqu&#234;mico. </p>
    <p> Esses passos envolvem mecanismos enzim&#225;ticos e proteases ativadoras do plasminog&#234;nio, metaloproteinases (MMP) da matriz extracelular (MEC) e cinases que provocam a degrada&#231;&#227;o molecular proteol&#237;tica da MEC, bem como pela ativa&#231;&#227;o e a libera&#231;&#227;o de fatores de crescimento, tais como: fator b&#225;sico de crescimento dos fibroblastos (FCFb), VEGF e fator de crescimento insul&#237;nico-1 (FCI-1). Posteriormente, vem a fase intermedi&#225;ria de estabiliza&#231;&#227;o do novo broto neovascular imaturo e a fase final de matura&#231;&#227;o vascular da angiog&#234;nese fisiol&#243;gica. </p>
    <p> Como conclus&#245;es generaliz&#225;veis, &#233; poss&#237;vel afirmar que a angiog&#234;nese coron&#225;ria em adultos &#233;, fundamentalmente, uma resposta par&#225;crina da rede capilar preexistente em condi&#231;&#245;es fisiopatol&#243;gicas de isquemia e inflama&#231;&#227;o.</p>
    <p><bold>Palavras-chave:</bold> Isquemia mioc&#225;rdica, neovasculariza&#231;&#227;o fisiol&#243;gica, c&#233;lulas endoteliais, adulto.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Nesta revis&#227;o, aborda-se a angiog&#234;nese mioc&#225;rdica end&#243;gena no adulto, sob uma &#243;tica unificada dos diversos mecanismos moleculares descritos. Essa vis&#227;o se baseia na interpreta&#231;&#227;o "din&#226;mica" da defini&#231;&#227;o cunhada por Folkman: "Angiog&#234;nese &#233; a gera&#231;&#227;o e a expans&#227;o de vasos sangu&#237;neos a partir de uma rede vascular preexistente, sob est&#237;mulos end&#243;genos ou ex&#243;genos"<sup>1</sup>. No adulto, angiog&#234;nese &#233;, em grande parte, uma resposta adaptativa &#224; hip&#243;xia tecidual e ocorre em uma ampla variedade de situa&#231;&#245;es, que v&#227;o desde desenvolvimento embrion&#225;rio at&#233; crescimento tumoral<sup>2</sup>. </p>
    <p>Mediando a cascata de eventos celulares e moleculares, est&#225; a ativa&#231;&#227;o do FIH- 1, que serve para aumentar a transcri&#231;&#227;o pelas CE, em sofrimento isqu&#234;mico, do VEGF e seus receptores VEGF-R<sup>3</sup>. </p>
    <p>Acredita-se que a rede capilar preexistente &#233; o lugar de in&#237;cio comum, no desenvolvimento e na gera&#231;&#227;o dos novos capilares, mediada pelos diferentes sistemas de sinais que desencadeiam a produ&#231;&#227;o de fatores de crescimento e que terminam induzindo a prolifera&#231;&#227;o das c&#233;lulas endoteliais. A defini&#231;&#227;o de angiog&#234;nese feita por Folkman, citada, baseia-se em s&#243;lidos elementos an&#225;tomo-morfom&#233;tricos.</p>
    <p>A rela&#231;&#227;o capilar/fibra mioc&#225;rdica normal no cora&#231;&#227;o do adulto &#233; de 1 para 1, ou seja, um capilar por fibra mioc&#225;rdica. O calibre m&#225;ximo de novos vasos identificados no processo de angiog&#234;nese &#233; de 200 &#181;m de di&#226;metro<sup>4</sup>. Se n&#227;o houver circula&#231;&#227;o coron&#225;ria epic&#225;rdica de alimenta&#231;&#227;o de dita circula&#231;&#227;o colateral com fluxo sangu&#237;neo adequado, &#233; prov&#225;vel que ocorra a regress&#227;o paulatina do processo de angiog&#234;nese. Por sua vez, cada fibra do mioc&#225;rdio tem di&#226;metro que varia de 10 a 25 &#181;m e o comprimento varia de 50 a 100 &#181;m, com distribui&#231;&#227;o capilar uniforme na parede ventricular esquerda de 3.000 para 4.000/cm<sup>2 5</sup>.</p>
    <p>Portanto, podemos dizer que essa defini&#231;&#227;o tem forte sustenta&#231;&#227;o morfom&#233;trica. Isso significa que, no cora&#231;&#227;o adulto normal em repouso, para que se mantenha a vida celular, deve existir uma fonte de nutrientes ao cora&#231;&#227;o. Em outras palavras, as c&#233;lulas progenitoras endoteliais circulantes (CPEc) requerem circula&#231;&#227;o coronariana preexistente para chegar ao local em que ocorre a isquemia mioc&#225;rdica.</p>
    <p>Ao analisar o segundo componente da defini&#231;&#227;o de Folkman, quando diz: "[...] por est&#237;mulos end&#243;genos ou ex&#243;genos...", verifica-se que abrangeu os dois principais mecanismos do processo de angiog&#234;nese: a end&#243;gena s&#227;o os processos fisiol&#243;gicos e patol&#243;gicos, enquanto a ex&#243;gena &#233; a terapia angiog&#234;nica cardiovascular como forma ex&#243;gena de indu&#231;&#227;o de angiog&#234;nese. O objetivo desta revis&#227;o &#233; analisar os mecanismos da angiog&#234;nese end&#243;gena nos processos fisiol&#243;gicos.</p>
    <p>
      <bold>I. Fases da regula&#231;&#227;o dos mecanismos indutores de angiog&#234;nese mioc&#225;rdica end&#243;gena no adulto:</bold>
    </p>
    <p>
      <bold>1. Fase inicial: isquemia mioc&#225;rdica como est&#237;mulo inicial</bold>
    </p>
    <p>A angiog&#234;nese &#233;, principalmente, uma resposta adaptativa &#224; hip&#243;xia tecidual e depende do ac&#250;mulo de FIH-1 &#945;, que, em condi&#231;&#245;es de hip&#243;xia tecidual, ativa a express&#227;o de fatores de crescimento e inicia o processo de angiog&#234;nese na zona isqu&#234;mica, a partir da rede coronariana preexistente<sup>6</sup>. Al&#233;m disso, a atra&#231;&#227;o e o recrutamento de CPEc e macr&#243;fagos ativam, de forma par&#225;crina, a angiog&#234;nese nessa &#225;rea<sup>7</sup>. A express&#227;o do VEGF-A &#233; um indicativo do recrutamento dos progenitores mieloides no mioc&#225;rdio isqu&#234;mico, enquanto as c&#233;lulas perivasculares da angiog&#234;nese s&#227;o mediadas pelos fatores derivados de c&#233;lulas estromais (FDE)-1 (<xref ref-type="fig" rid="a19fig01m">Figura 1</xref>)<sup>8</sup>. </p>
    <p content-type="asset">
      <fig id="a19fig01m">
        <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf01.jpg"/></fig>
    </p>
    <p>Na cardiopatia isqu&#234;mica, tanto FIH-1&#945; quanto VEGF-A est&#227;o presentes na placa ateroscler&#243;tica, sugerindo que o FIH, por via da sinaliza&#231;&#227;o angiog&#234;nica, est&#225; diretamente envolvido no crescimento da placa ateroscler&#243;tica<sup>9</sup>. </p>
    <p>A isquemia mioc&#225;rdica grave leva ao ac&#250;mulo de FIH-1 e &#224; express&#227;o de fatores que estimulam brotos angiog&#234;nicos nas proximidades dos vasos sangu&#237;neos no mioc&#225;rdio isqu&#234;mico. N&#227;o podemos esquecer que a isquemia grave e persistente causa apoptose da CE e das fibras mioc&#225;rdicas. Al&#233;m disso, os progenitores mieloides e endoteliais derivados da medula &#243;ssea tamb&#233;m s&#227;o recrutados para participar ativamente do apoio da angiog&#234;nese<sup>10</sup>. </p>
    <p>O FIH-1&#945; &#233; claramente importante para a angiog&#234;nese no mioc&#225;rdio. No entanto, pouco se sabe a respeito do FIH-2&#945;. Cardiomi&#243;citos privados de FIH-1&#945; espec&#237;ficos foram levados a redu&#231;&#227;o da vasculariza&#231;&#227;o, altera&#231;&#245;es no metabolismo energ&#233;tico e anormalidade da fun&#231;&#227;o contr&#225;til. Em contrapartida, a superexpress&#227;o da prote&#237;na de fus&#227;o FIH-1&#945;/VP16 (FIH-1&#945; do ADN vinculante e ativador de dom&#237;nio ligado com heterodimerization VP16) foi capaz de promover a angiog&#234;nese e reduzir o tamanho de infarto em modelo experimental em rato. Tal como ocorre com outros tecidos hip&#243;xicos, o FIH-1&#945; &#233; essencial para o aumento da concentra&#231;&#227;o, na medula &#243;ssea, de precursores de CE. Mesmo uma defici&#234;ncia parcial de FIH-1&#945;, decorrente de envelhecimento, est&#225; associada a uma redu&#231;&#227;o significativa na concentra&#231;&#227;o dessas c&#233;lulas e a uma pobre vasculariza&#231;&#227;o em m&#250;sculo isqu&#234;mico<sup>11</sup>. </p>
    <p>A hipoxemia tamb&#233;m regula a produ&#231;&#227;o e a express&#227;o do VEGF, em raz&#227;o do aumento da transcri&#231;&#227;o do FIH-1 e do aumento na estabilidade do VEGF-dependente da regi&#227;o 3 do ARNm<sup>11</sup>. </p>
    <p>O mecanismo molecular iniciador da angiog&#234;nese pode ser impulsionado pela priva&#231;&#227;o de oxig&#234;nio e nutrientes, como glicose, que regulam a express&#227;o g&#234;nica. Observou-se tamb&#233;m que a hip&#243;xia regula os receptores TIE-2, sendo moduladores da atividade do VEGF, o que leva as CE a proliferar pelos mecanismos de brotamento ou divis&#227;o. De acordo com o padr&#227;o de sinal do VEGF e TIE-2, &#233; poss&#237;vel induzir angiog&#234;nese por brotos ou intussuscep&#231;&#227;o<sup>12</sup>. Um fato importante, de aplica&#231;&#227;o terap&#234;utica do VEGF, &#233; que a isquemia estimula sua express&#227;o, bem como a de seus receptores<sup>13</sup> (<xref ref-type="fig" rid="a19fig01m">Figura 1</xref>).</p>
    <p>
      <bold>1.1. Mecanismo de angiog&#234;nese por atra&#231;&#227;o de c&#233;lulas tronco circulantes durante o infarto agudo do mioc&#225;rdio</bold>
    </p>
    <p>Durante a isquemia mioc&#225;rdica, o aumento da express&#227;o e estabiliza&#231;&#227;o da transcri&#231;&#227;o de FIH-1 promove produ&#231;&#227;o local e libera&#231;&#227;o pela CE em sofrimento isqu&#234;mico dos fatores FDE-1 e VEGF-A<sup>14</sup>. O FIH circulante regula muitos genes da angiog&#234;nese, mas a indu&#231;&#227;o do VEGF talvez seja o mais not&#225;vel. FIH aumenta a concentra&#231;&#227;o local de VEGF em at&#233; 30 vezes, em poucos minutos. O VEGF estimula a angiog&#234;nese fisiol&#243;gica e patol&#243;gica em estrita resposta dose-dependente<sup>6</sup>. Esses mediadores s&#227;o capazes de aumentar a mobiliza&#231;&#227;o e o recrutamento das CPEc na &#225;rea isqu&#234;mica<sup>15</sup>. </p>
    <p>O aumento da express&#227;o de FDE-1 &#233; essencial para regula&#231;&#227;o da atra&#231;&#227;o, migra&#231;&#227;o e reten&#231;&#227;o seletiva, no tecido mioc&#225;rdico isqu&#234;mico, das CPEc ou das CE com o receptor de superficie 4 da quemoquina CXC-R4<sup>16</sup>. Isso significa que a via FIH-1 &#233; o mecanismo de unifica&#231;&#227;o do sistema de sinaliza&#231;&#227;o da angiog&#234;nese, no contexto do infarto agudo do mioc&#225;rdio (<xref ref-type="fig" rid="a19fig01m">Figura 1</xref>).</p>
    <p>Essas CPEc, do mesmo modo que ocorre com as c&#233;lulas mesenquimais da medula &#243;ssea (entre outras), s&#227;o mobilizadas, atra&#237;das e deslocadas da circula&#231;&#227;o perif&#233;rica para as &#225;reas de isquemia mioc&#225;rdica<sup>17</sup>. </p>
    <p>H&#225; evid&#234;ncia de que FDE-1 com o receptor de sinal CXC-R4 + desempenha papel importante no recrutamento de c&#233;lulas circulantes da medula &#243;ssea no contexto de uma grave isquemia mioc&#225;rdica. Esse sinal &#233; essencial para o recrutamento de c&#233;lulas-tronco no cora&#231;&#227;o. O CXC-R4 + &#233; um receptor de superf&#237;cie celular da FDE-1, expresso nas CPEc e nas c&#233;lulas-tronco circulantes hematopo&#233;ticas (CTHc)<sup>18</sup>. </p>
    <p>As CPEc desempenham papel importante na manuten&#231;&#227;o da parede vascular endotelial, auxiliando na reendoteliza&#231;&#227;o (mudan&#231;a fisiol&#243;gica das CE) e na angiog&#234;nese<sup>19</sup>. </p>
    <p>No entanto, os n&#237;veis de FDE-1 end&#243;geno secretado diminuem ap&#243;s o IAM e retornam ao n&#237;vel normal ap&#243;s o 4&#186; ou 7&#186; dias do IAM<sup>20</sup>. </p>
    <p>As c&#233;lulas mesenquimais circulantes derivadas da medula &#243;ssea (CMcDMO) constituem uma ponte para o interior de mioc&#225;rdio isqu&#234;mico, expresso pelo FDE-1, que poder&#225; ser um sinal facilitador para a migra&#231;&#227;o de c&#233;lulas circulantes e da medula &#243;ssea<sup>17</sup>. </p>
    <p>Acreditava-se que os precursores endoteliais existiam apenas durante a vida embrion&#225;ria. Atualmente, foram identificados precursores na medula &#243;ssea e em vasos perif&#233;ricos no adulto. Alguns fatores de crescimento, como o fator estimulador de col&#244;nias de granul&#243;citos (FECG), b-FCF e FCI-1, estimulam sua diferencia&#231;&#227;o e sua mobiliza&#231;&#227;o<sup>21</sup>. Esses precursores de c&#233;lulas endoteliais colonizam novas &#225;reas de brotos angiog&#234;nicos no adulto e, no futuro, podem ser alvos terap&#234;uticos.</p>
    <p>Rehman e cols.<sup>22</sup> t&#234;m questionado a origem dessas CPEc e sua verdadeira incorpora&#231;&#227;o na parede dos vasos em crescimento. Descobriram que a maior parte das chamadas CPEc deriva de mon&#243;citos/macr&#243;fagos, com apenas uma pequena popula&#231;&#227;o de c&#233;lulas-tronco CD-34<sup>+</sup>/c&#233;lulas progenitoras hematopo&#233;ticas a partir de c&#233;lulas tronco/angioblastos. Esses mon&#243;citos/macr&#243;fagos secretam m&#250;ltiplos fatores de crescimento angiog&#234;nicos, que promovem, com sua estimula&#231;&#227;o par&#225;crina, o crescimento neovascular<sup>22</sup>. </p>
    <p>O conceito de CPEc &#233; muito atrativo, por&#233;m, mais de uma d&#233;cada ap&#243;s sua descoberta, ainda n&#227;o existem marcadores espec&#237;ficos das CPEc e os resultados dos ensaios cl&#237;nicos ainda s&#227;o controversos. Empregando um enfoque prote&#244;mico, um estudo recente mostra que as c&#233;lulas com fen&#243;tipo de CPEc poderiam ser c&#233;lulas mononucleares circulantes com a incorpora&#231;&#227;o de micropart&#237;culas de plaquetas<sup>23</sup>. </p>
    <p>Schmeisser e cols.<sup>24</sup> demonstraram que o mon&#243;cito CD-34<sup>+</sup> pode desenvolver <italic>in vitro</italic> um fen&#243;tipo endotelial e tomar forma em uma estrutura tubular, o que sugere um potencial papel dos mon&#243;citos na angiog&#234;nese<sup>24</sup>. </p>
    <p>Finalmente, Ziegelhoeffer e cols.<sup>25</sup> publicaram um estudo que aponta para o fato de que, no organismo adulto, as c&#233;lulas-tronco provenientes da medula &#243;ssea n&#227;o promovem crescimento vascular pela incorpora&#231;&#227;o nas paredes vasculares, mas sim atrav&#233;s de m&#250;ltiplos efeitos par&#225;crinos de citocinas angiog&#234;nicas<sup>25</sup>. </p>
    <p>Resumindo: a angiog&#234;nese &#233; um mecanismo fisiol&#243;gico organizado sob rigorosa regula&#231;&#227;o, com muitos fatores que influenciam o processo ativo em n&#237;vel molecular, incluindo muitos polipept&#237;dios sol&#250;veis, como VEGF, angiopoietina, FCF, fatores de crescimento derivado de plaquetas (FCDP), fator de crescimento transformador &#946; (FCT-&#946;), fator de necrose tumoral (FNT)-&#945;, FECG, entre muitos outros<sup>26</sup>. </p>
    <p>
      <bold>1.2. Mecanismo de angiog&#234;nese end&#243;gena por ativa&#231;&#227;o de c&#233;lulas-tronco residentes no cora&#231;&#227;o</bold>
    </p>
    <p>O verdadeiro papel desse mecanismo e da quantifica&#231;&#227;o de seu efeito angiog&#234;nico &#233; incerto. C&#233;lulas-tronco residentes do mioc&#225;rdio (CTRM) foram capazes de se diferenciar em cardiomi&#243;citos, c&#233;lulas endoteliais e c&#233;lulas musculares lisas<sup>27</sup>. Essas CTRMs expressam receptores para FCH e para FCI-1, que podem levar ao recrutamento e &#224; prolifera&#231;&#227;o das CE e repor algumas fun&#231;&#245;es do cora&#231;&#227;o com dano isqu&#234;mico. Assim como ocorre com as c&#233;lulas mesenquimais circulantes (MSCc), que s&#227;o capazes de secretar FCH e FCI-1 em resposta &#224; les&#227;o<sup>28</sup>. </p>
    <p>
      <bold>1.3. Prolifera&#231;&#227;o de c&#233;lulas endoteliais como resposta final comum da isquemia mioc&#225;rdica: gera&#231;&#227;o de broto vascular angiog&#234;nico</bold>
    </p>
    <p>Em adultos, esse processo se deve, principalmente, &#224; hipoxemia e se encontra mediado pela ativa&#231;&#227;o de FIH-1&#945;, que serve para aumentar a transcri&#231;&#227;o do VEGF e seus receptores VEGFRs<sup>2</sup>. </p>
    <p>O VEGF estimula a angiog&#234;nese fisiol&#243;gica e patol&#243;gica em estrita rela&#231;&#227;o dose-dependente<sup>29</sup>. O VEGF &#233; uma prote&#237;na que tem a caracter&#237;stica espec&#237;fica de estimular a replica&#231;&#227;o de c&#233;lulas endoteliais vasculares, essenciais para a angiog&#234;nese<sup>30</sup>. O VEGF-A se liga a dois receptores tirosina-quinase (RTK), VEGFR-1 (flt-1) e VEGFR-2 (KDR, Flk-1). Receptores tirosina-quinase flt-1 (VEGF-R1) constituem a segunda maior afinidade para o VEGF. Embora n&#227;o t&#227;o espec&#237;fico, o receptor flk-1 n&#227;o compartilha afinidades com c&#233;lulas do sistema inflamat&#243;rio, como, por exemplo, mon&#243;citos ou c&#233;lulas cancerosas, ao contr&#225;rio do receptor flt -1. Num recente e elegante trabalho da Universidade de Leuven, fez-se importante descoberta com implica&#231;&#245;es terap&#234;uticas para o futuro, qual seja, a relativa especificidade do VEGF-B, em termos de sua atividade angiog&#234;nica no tecido mioc&#225;rdico isqu&#234;mico<sup>31</sup>. </p>
    <p>No mecanismo da angiog&#234;nese, devido ao crescimento vascular em forma de broto vascular, &#233; poss&#237;vel determinar os seguintes passos de maneira simplificada:</p>
    <p>a) vasodilata&#231;&#227;o inicial, processo que envolve &#243;xido n&#237;trico e VEGF<sup>32</sup>; </p>
    <p>b) aumento da permeabilidade vascular em resposta ao VEGF, como extravasamento de prote&#237;nas plasm&#225;ticas que funcionam como suporte para a migra&#231;&#227;o das c&#233;lulas endoteliais (CE). O aumento da permeabilidade &#233; produzido pela forma&#231;&#227;o de fenestra&#231;&#245;es organo-vesiculares e pela redistribui&#231;&#227;o das mol&#233;culas de ades&#227;o celular endotelial plaquet&#225;ria<sup>33</sup>; </p>
    <p>c) degrada&#231;&#227;o proteol&#237;tica da MEC: as proteinases exp&#245;em prote&#237;nas da MEC degradada, como col&#225;geno IV e mon&#244;mero de col&#225;geno fibrilar, que induzem a migra&#231;&#227;o de CE e CML<sup>34</sup>. </p>
    <p>Os tr&#234;s passos descritos envolvem mecanismos enzim&#225;ticos que incluem a Ang2, um inibidor de TIE2<sup>35</sup>, proteases ativadoras do plasminog&#234;nio, metaloproteinases (MMP) da MEC e cinases ou fam&#237;lia das heparinases.</p>
    <p>Todas as proteases influenciam na angiog&#234;nese atrav&#233;s da degrada&#231;&#227;o molecular proteol&#237;tica da MEC, e da ativa&#231;&#227;o e libera&#231;&#227;o do fator de crescimento, como bFCF, VEGF e IGF1, sequestrado na matriz extracelular (Quadro 8 na <xref ref-type="fig" rid="a19fig02m">Figura 2</xref>)<sup>36</sup>. Tamb&#233;m exercem a&#231;&#227;o proteol&#237;tica o fator de crescimento transformador (FCT) e a ativa&#231;&#227;o proteol&#237;tica de quimioquinas angiog&#234;nicas como o IL-1. Ou seja, durante o remodelamento vascular por brota&#231;&#227;o, ocorre degrada&#231;&#227;o proteol&#237;tica, incluindo ativadores de plasminog&#234;nio como a urocinase ativadora do plaminog&#234;nio (UPA) e seu inibidor PAI-1, matriz metaloproteinases (MMPs) e inibidores da metaloproteinases dos tecidos (TIMPs), heparinases, quinases, tirosinases e caderinases<sup>37</sup>. </p>
    <p content-type="asset">
      <fig id="a19fig02m">
        <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf02.jpg"/></fig>
    </p>
    <p>Ao analisar o papel cr&#237;tico da degrada&#231;&#227;o proteol&#237;tica da MEC no crescimento e na manuten&#231;&#227;o do broto angiog&#234;nico, devem ser considerados os limites de tempo de dito processo. O processo tamb&#233;m deve ser equilibrado, porque degrada&#231;&#227;o insuficiente impede que as c&#233;lulas vasculares deixem suas posi&#231;&#245;es originais. Por outro lado, a excessiva degrada&#231;&#227;o impede o apoio e a orienta&#231;&#227;o para a migra&#231;&#227;o das CE e, consequentemente, tamb&#233;m a angiog&#234;nese<sup>38</sup>. </p>
    <p>No processo de angiog&#234;nese, uma vez produzida a degrada&#231;&#227;o proteol&#237;tica da MEC, seguida por fragmenta&#231;&#227;o da membrana basal, produz-se a migra&#231;&#227;o quimiot&#225;tica das c&#233;lulas endoteliais atrav&#233;s da membrana basal. Para que isso aconte&#231;a, &#233; necess&#225;rio que as conex&#245;es intercelulares endoteliais sejam degradadas. Quando as CE migram para formar novos brotos, a MEC sofre degrada&#231;&#227;o proteol&#237;tica e mudan&#231;as em sua composi&#231;&#227;o (<xref ref-type="fig" rid="a19fig03m">Figura 3</xref>).</p>
    <p content-type="asset">
      <fig id="a19fig03m">
        <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf03.jpg"/></fig>
    </p>
    <p>A migra&#231;&#227;o das CE ocorre 24 horas antes dos seguintes processos:</p>
    <p>a) prolifera&#231;&#227;o;</p>
    <p>b) ades&#227;o e reestabelecimento de contatos intracelulares;</p>
    <p>c) forma&#231;&#227;o do l&#250;men vascular;</p>
    <p>d) matura&#231;&#227;o funcional do endot&#233;lio.</p>
    <p>Como se pode apreciar, as proteases desempenham papel cr&#237;tico no processo de angiog&#234;nese<sup>39</sup>. </p>
    <p>A estimula&#231;&#227;o do VEGF sobre os receptores de membrana tirosina-quinase das c&#233;lulas endoteliais vasculares &#233; expressa atrav&#233;s de membros de gens Src da familia das tirisina-quinase, como o Src, Fyn, Yes, que regulam m&#250;ltiplas fun&#231;&#245;es intracelulares. Em primeiro lugar, Src, Fyn e Yes desempenham, cada qual, papel &#250;nico no sistema de sinaliza&#231;&#227;o mitog&#234;nica do VEGF. Em segundo lugar, eles contribuem para a modula&#231;&#227;o do VEGF na migra&#231;&#227;o celular. Em terceiro lugar, Fyn desempenha papel &#250;nico na indu&#231;&#227;o de VEGF para a forma&#231;&#227;o do tubo neovascular. O Fyn tem um efeito regulador negativo sobre a migra&#231;&#227;o e a estabiliza&#231;&#227;o do tubo neovascular induzido pelo VEGF. Esses resultados fornecem provas diretas de que Src, Fyn e Yes t&#234;m importante papel na regula&#231;&#227;o do VEGF nos eventos mediados pelas c&#233;lulas endoteliais<sup>40</sup>. </p>
    <p>A exist&#234;ncia de tubos com pericitos reflete o in&#237;cio precoce da participa&#231;&#227;o de pericito na angiog&#234;nese intussusceptiva (ver Quadro 4 da <xref ref-type="fig" rid="a19fig02m">Figura 2</xref>). A cria&#231;&#227;o de uma rede vascular funcional exige que os brotos vasculares emergentes maturem e permane&#231;am funcionais ao longo do tempo. A associa&#231;&#227;o do pericito e do CML com os brotos de recente forma&#231;&#227;o das CE regula sua prolifera&#231;&#227;o, sobreviv&#234;ncia, migra&#231;&#227;o, diferencia&#231;&#227;o, ramifica&#231;&#227;o vascular, fluxo sangu&#237;neo e permeabilidade vascular. A participa&#231;&#227;o precoce dos pericitos no desenvolvimento da microvasculatura tem importantes implica&#231;&#245;es para a interven&#231;&#227;o terap&#234;utica em muitas doen&#231;as<sup>41</sup>. </p>
    <p>O fluxo sangu&#237;neo, com sua press&#227;o sobre a nova parede vascular, interage de forma integrada e din&#226;mica com o citoesqueleto e a MEC. O fluxo sangu&#237;neo cont&#237;nuo estimula a prolifera&#231;&#227;o das c&#233;lulas endoteliais e regula VEGF, integrina aVb3, PECAM-1 e VE-caderina. A tens&#227;o de cisalhamento ("shear stress") estimula a prolifera&#231;&#227;o de c&#233;lulas endoteliais e, consequentemente, aumenta o di&#226;metro do vaso<sup>42</sup>. </p>
    <p>A MEC fornece os contatos necess&#225;rios entre as CE e os tecidos circundantes, impedindo que os brotos neovasculares degenerem. Uma matriz de col&#225;geno intersticial e elastina entre as c&#233;lulas vasculares oferece propriedades de viscoelasticidade e resist&#234;ncia &#224; parede do vaso. A MEC tamb&#233;m regula a forma&#231;&#227;o do novo broto vascular. Quando as c&#233;lulas endoteliais migram para formar novos brotos vasculares, a matriz n&#227;o apenas &#233; rompida proteoliticamente, como tamb&#233;m sua composi&#231;&#227;o &#233; alterada. Proteinases exp&#245;em novos ep&#237;topos nas prote&#237;nas da MEC (por exemplo, o col&#225;geno IV) ou alteram sua estrutura (mon&#244;meras de col&#225;geno fibrilar), levando &#224; migra&#231;&#227;o das CE e CML<sup>34</sup>. Al&#233;m disso, fibronectina, fibrina e outros componentes da matriz fornecem um andaime para o apoio e as orienta&#231;&#245;es das CE.</p>
    <p>As integrinas s&#227;o receptores de superf&#237;cie celular espec&#237;ficos da MEC, que, por transmiss&#227;o de informa&#231;&#245;es bidirecionais entre o exterior e o interior de c&#233;lulas vasculares, ajudam a construir novos brotos vasculares de maneira coordenada. As integrinas &#945;5&#946;3 e &#945;5&#946;5 t&#234;m sido, h&#225; muito tempo, consideradas um regulador positivo da angiog&#234;nese, porque seus antagonistas farmacol&#243;gicos suprimem a angiog&#234;nese patol&#243;gica<sup>43</sup>. </p>
    <p>O fator de crescimento derivado das plaquetas (FCDP) - &#946; e de seu receptor FCDP-R&#946; desempenha papel essencial na estabiliza&#231;&#227;o dos vasos sangu&#237;neos nascentes, recrutando c&#233;lulas mesenquimais FCDP-R&#946; positivo. A falta de recrutamento das CE tem como resultado um crescimento neovascular patol&#243;gico, o que provoca: altera&#231;&#227;o da permeabilidade neovascular, fragilidade neovascular, sangramento, insufici&#234;ncia de perfus&#227;o e hip&#243;xia em embri&#245;es que t&#234;m car&#234;ncia de FCDP-&#946;<sup>44</sup>. Em vez disso, uma combina&#231;&#227;o de FCDP-&#946; e VEGF resulta na forma&#231;&#227;o de brotos vasculares mais maduros do que em monoterapia com qualquer dos fatores. Isso &#233; muito importante para o futuro desenvolvimento de estrat&#233;gias terap&#234;uticas da angiog&#234;nese.</p>
    <p>Outro sistema de sinaliza&#231;&#227;o envolvido na manuten&#231;&#227;o, crescimento e estabiliza&#231;&#227;o do broto neovascular nascente &#233; o receptor TIE-2, que liga as angiopoietinas Ang-1 e Ang-2. Diferentemente da Ang-2, que ativa a TIE-2 em algumas c&#233;lulas, mas bloqueia o TIE-2 em outras, a Ang-1 consistentemente ativa o receptor TIE-2. A Ang-1, por sua vez, compacta os brotos neovasculares nascentes, atrav&#233;s das mol&#233;culas de liga&#231;&#227;o, e promove intera&#231;&#227;o entre as CE das paredes como um adesivo de prote&#237;nas e contra&#231;&#227;o de pericitos. A atividade angiog&#234;nica da Ang-2 est&#225; em sinergia com o VEGF para estimular a angiog&#234;nese no cora&#231;&#227;o, mas, quando os sinais n&#227;o s&#227;o suficientes, causa a morte das CE e a regress&#227;o do broto neovascular nascente. Ou seja, os sinais de ativa&#231;&#227;o TIE-2 devem funcionar como uma balan&#231;a de precis&#227;o<sup>45</sup>. </p>
    <p>
      <bold>2. Fase intermedi&#225;ria: a estabiliza&#231;&#227;o do novo broto neovascular imaturo</bold>
    </p>
    <p>O broto nascente neovascular &#233; estabilizado atrav&#233;s do recrutamento de c&#233;lulas murais e pela gera&#231;&#227;o de uma nova MEC. Pelo menos quatro vias moleculares est&#227;o envolvidas na regula&#231;&#227;o desse processo: FCDP e seu receptor &#946; (FCDP-R&#946;); esfingosina-1/fosfato-1 (S1P1); fator de diferencia&#231;&#227;o endotelial (receptor prote&#237;na esfingosina G-1 (EDG1); Ang1-TIE-2 e o FCT. O FCDP-&#946; &#233; secretado pela CE, presumivelmente em resposta ao VEGF. Embora o FCDP-&#946; seja expressado pelas CE e as c&#233;lulas murais, s&#227;o estas as respons&#225;veis durante a fase de matura&#231;&#227;o da angiog&#234;nese. Tamb&#233;m s&#227;o essenciais, para a forma&#231;&#227;o e a estabiliza&#231;&#227;o do broto neovascular, os receptores TIE-1 e TIE-2, e os dois ligantes para TIE-2, como Ang1 e Ang2. As principais fontes de Ang1 e Ang2 s&#227;o, respectivamente, as CE parietais e as CE de &#243;rg&#227;os espec&#237;ficos. O Ang1 &#233; conhecida pela estabiliza&#231;&#227;o dos brotos vasculares emergentes e por torn&#225;-los resistentes &#224; fuga entre conex&#245;es intercelulares. Na aus&#234;ncia de VEGF, a Ang2 atua como um antagonista da Ang1 e desestabiliza o broto neovascular nascente, levando, finalmente, &#224; sua regress&#227;o. Na presen&#231;a de VEGF, Ang2 facilita a angiog&#234;nese. O FCT-&#946;1 &#233; uma citoquina multifuncional que promove o ciclo de matura&#231;&#227;o do broto noevascular em desenvolvimento pela estimula&#231;&#227;o da MEC, ao estimular a indu&#231;&#227;o e a diferencia&#231;&#227;o de c&#233;lulas mesenquimais em CE murais<sup>46</sup>. </p>
    <p>
      <bold>3. Fase final: matura&#231;&#227;o vascular da angiog&#234;nese fisiol&#243;gica</bold>
    </p>
    <p>Os determinantes moleculares de matura&#231;&#227;o neovascular podem ser agrupados em tr&#234;s categorias: I) Uni&#227;o dos fatores de crescimento a um tipo de receptor celular, com seu efeito correspondente; II) Regula&#231;&#227;o molecular das intera&#231;&#245;es celulares; III) Regula&#231;&#227;o molecular das intera&#231;&#245;es entre as c&#233;lulas endoteliais e a matriz extracelular.</p>
    <p>I) Uni&#227;o dos fatores de crescimento a um tipo de receptor celular, com seu efeito correspondente:</p>
    <p>a) Receptores de CE flt1y, flk1 (VEGF-R1, VEGF-R2): 1) Regula&#231;&#227;o das proteases na organiza&#231;&#227;o da MEC; 2) Gera&#231;&#227;o da MEC provis&#243;ria, que permite aumentar a permeabilidade; 3) Regula&#231;&#227;o do FCDP-&#946;, que recruta as c&#233;lulas para estabilizar a parede do vaso nascente; 4) Supress&#227;o da apoptose nos vasos nascentes; 5) Estabiliza&#231;&#227;o das CE.</p>
    <p>b) FCDP-R&#946;; Ang1/TIE-2: 1) Promo&#231;&#227;o de prolifera&#231;&#227;o, migra&#231;&#227;o e recrutamento das c&#233;lulas murais; 2) Estabiliza&#231;&#227;o de vasos nascentes, o que facilita as intera&#231;&#245;es entre as jun&#231;&#245;es intercelulares (CE-CE, CE-MEC); 3) Supress&#227;o da apoptose das CEc.</p>
    <p>c) Ang2/TIE1: induz apoptose das CE, na aus&#234;ncia de VEGF.</p>
    <p>d) Ang1/TIE1: coordenam a polaridade vascular.</p>
    <p>e) FCT-&#946;1/FCT-&#946;RII: </p>
    <p>1) Promovem a produ&#231;&#227;o de proteases e MEC.</p>
    <p>2) Promovem a diferencia&#231;&#227;o de fibroblastos para miofibroblastos.</p>
    <p>f) FCT-&#946;1/ALK1regulam a prolifera&#231;&#227;o e a migra&#231;&#227;o de CE.</p>
    <p>g) FCT-&#946;1/ALK5: regulam a matura&#231;&#227;o dos novos vasos.</p>
    <p>h) FCT-&#946;1/ALK1 e a endoglina: promovem a especializa&#231;&#227;o arterial e venosa.</p>
    <p>II) Regula&#231;&#227;o molecular das conex&#245;es intercelulares:</p>
    <p>a) V caderina: forma as uni&#245;es entre as CE.</p>
    <p>b) N-caderina: faz conex&#245;es entre as c&#233;lulas da parede celular e as CE.</p>
    <p>c) Conectinas: estabelece conex&#245;es entre as CE e as CE e c&#233;lulas parietais.</p>
    <p>III) Regula&#231;&#227;o molecular das intera&#231;&#245;es entre as CE e a MEC:</p>
    <p>a) &#945;5&#946;1, &#945;1&#946;1, &#945;2&#946;1, &#945;v&#946;3, &#945;v&#946;5: supress&#227;o da apoptose de CE.</p>
    <p>b) Proteases: em sua a&#231;&#227;o enzim&#225;tica, promovem a produ&#231;&#227;o da MEC, como, por exemplo, a clivagem do col&#225;geno XVIII para endostatina, o plasminog&#234;nio, a angiotensina e proteases como MMP2 e PEX.</p>
    <p>c) Proteases inibit&#243;rias: evitam a degrada&#231;&#227;o proteol&#237;tica da MEC para estabilizar o vaso.</p>
    <p>Esses dados suportam, de forma consistente, a hip&#243;tese de que Ang2 e VEGF levam &#224; forma&#231;&#227;o dos brotos neovasculares, enquanto Ang1 est&#225; envolvida na estabiliza&#231;&#227;o do broto, por intera&#231;&#227;o das CE e da c&#233;lula mural<sup>46</sup>. </p>
    <p>
      <bold>3.1. Forma&#231;&#227;o do l&#250;men vascular</bold>
    </p>
    <p>Durante o processo de angiog&#234;nese, ocorrem migra&#231;&#227;o e prolifera&#231;&#227;o de CE por aproximadamente 24 horas, per&#237;odo durante o qual as proteases desempenham papel crucial<sup>46</sup>. A prolifera&#231;&#227;o &#233; registrada no n&#237;vel das CE e CML<sup>47</sup>. </p>
    <p>O processo de forma&#231;&#227;o do l&#250;men vascular &#233; uma fase coordenada de ades&#227;o molecular-celular durante a extens&#227;o do vaso sangu&#237;neo. As mol&#233;culas espec&#237;ficas respons&#225;veis pela extens&#227;o do vaso n&#227;o s&#227;o bem conhecidas<sup>48</sup>. </p>
    <p>O receptor TIE-2 e de CE &#233; necess&#225;rio para o desenvolvimento de vasos sangu&#237;neos, bem como para sua manuten&#231;&#227;o e repara&#231;&#227;o. A Ang foi identificada como ligante espec&#237;fico para o receptor TIE-2. Como j&#225; citado, Ang-1 &#233; um agonista dos receptores TIE-2 que promove a sobreviv&#234;ncia das CE e reduz a permeabilidade vascular<sup>49</sup>. </p>
    <p>Em contraste com a Ang-1, a Ang-2 foi inicialmente descrita como antagonista que bloqueia a TIE-2/Ang-1 e leva &#224; ativa&#231;&#227;o do TIE-2, o que resulta na apoptose das CE. No sistema de sinaliza&#231;&#227;o das CE para sua sobreviv&#234;ncia e migra&#231;&#227;o, o TIE-2 &#233; componente essencial do desenvolvimento da vasculog&#234;nese embrion&#225;ria, assim como da angiog&#234;nese no adulto. Trabalhos recentes identificaram uma prote&#237;na tirosina fosfatase beta como uma nova CE-fosfatase espec&#237;fica que regula a sinaliza&#231;&#227;o Ang-1-TIE-2 das CE. Assim, estrat&#233;gias orientadas para HPTP-&#946; podem ser ben&#233;ficas &#224; sinaliza&#231;&#227;o da Ang1 e, portanto, melhoram a forma&#231;&#227;o e a matura&#231;&#227;o dos neovasos no contexto da angiog&#234;nese terap&#234;utica. Al&#233;m disso, &#233; poss&#237;vel concluir que a hip&#243;xia aumenta a express&#227;o de HPTP-&#946; e diminui a fosforila&#231;&#227;o da TIE-2, o que lan&#231;a nova luz sobre o papel potencial da angiog&#234;nese do HPTP-&#946;. A indu&#231;&#227;o de HPTP-&#946; pela hip&#243;xia pode representar um importante mecanismo regulador de ativa&#231;&#227;o do TIE-2 na angiog&#234;nese patol&#243;gica<sup>50</sup>. </p>
    <p>Em resumo, as CE t&#234;m um receptor tirosina-quinase seletiva; o TIE-2 e seus ligantes, a angiopoietina Ang-1 e Ang-2, por sua vez, s&#227;o essenciais para a manuten&#231;&#227;o e a repara&#231;&#227;o dos vasos sangu&#237;neos. A Ang-1 &#233; um agonista da ativa&#231;&#227;o dos receptores TIE-2. No entanto, a Ang-2 &#233; contexto-dependente, ou seja, pode ser antagonista ou agonista. A prote&#237;na tirosina-fosfatase beta (HPTP-&#946;) desempenha papel relevante na sobreviv&#234;ncia das c&#233;lulas endoteliais, modulando a sinaliza&#231;&#227;o de Ang-1-TIE-2.</p>
    <p>
      <bold>3.2. Permeabilidade neovascular</bold>
    </p>
    <p>O VEGF leva &#224; prolifera&#231;&#227;o e &#224; migra&#231;&#227;o das CE no processo da angiog&#234;nese. Foi inicialmente identificado como fator de permeabilidade vascular (VPF). Muitas evid&#234;ncias sugerem que a angiog&#234;nese &#233; precedida e/ou acompanhada de aumento da permeabilidade<sup>4</sup>. </p>
    <p>Os mecanismos pelos quais VEGF/VPF aumentam a permeabilidade vascular (PV) persistem desconhecidos. Murohara e cols.<sup>51</sup> identificam o &#243;xido n&#237;trico (ON) na regula&#231;&#227;o da PV, enquanto van der Zee e cols<sup>52</sup> identificaram, <italic>in vitro</italic>, que o VEGF/VPF estimula a produ&#231;&#227;o de ON no endot&#233;lio macrovascular. </p>
    <p>Isner<sup>4</sup> demonstrou a a&#231;&#227;o sin&#233;rgica entre ON e prostaciclinas produzida pela intera&#231;&#227;o do VEGF/VPF com seu receptor Flk-1/KDR/VEGF-R2 como mediador da permeabilidade vascular induzida por VEGF/VPF, constituindo uma propriedade &#250;nica do VEGF/VPF entre as citocinas angiog&#234;nicas. Quando as proteases foram avaliadas por sua capacidade de aumentar a permeabilidade pelo teste de Miles, o VEGF foi o &#250;nico a aumentar a permeabilidade - o mecanismo de a&#231;&#227;o, contudo, &#233; desconhecido. O &#243;xido n&#237;trico tem sido implicado como um fator regulador da permeabilidade, dependendo de sua concentra&#231;&#227;o local<sup>4</sup>. </p>
    <p>Existem tr&#234;s tipos diferentes de permeabilidade vascular:</p>
    <p>1) permeabilidade da membrana basal vascular (PBV), presente nos tecidos normais;</p>
    <p>2) aumento da permeabilidade vascular produzido em resposta a uma &#250;nica e breve exposi&#231;&#227;o a VEGF-A ou a outros agentes;</p>
    <p>3) aumento cr&#244;nico da permeabilidade vascular, que caracteriza a angiog&#234;nese patol&#243;gica.</p>
    <p>Finalmente, observou-se que o VEGF-A varia significativamente em diferentes cepas do rato, e &#233; prov&#225;vel que a resposta da permeabilidade, tanto basal quanto induzida por alguns fatores, tamb&#233;m difere em camundongos com diferentes estruturas gen&#233;ticas, embora isso ainda n&#227;o tenha sido investigado de forma sistem&#225;tica<sup>53</sup>. </p>
    <p>
      <bold>II. Respostas das C&#233;lulas Vasculares &#224; Hip&#243;xia</bold>
    </p>
    <p>A hip&#243;xia leva ao aumento da sinaliza&#231;&#227;o atrav&#233;s da transcri&#231;&#227;o do FIH-1.</p>
    <p>
      <bold>1. C&#233;lulas endoteliais</bold>
    </p>
    <p>Existem dois mecanismos identificados na hipoxemia que est&#227;o ligados &#224; angiog&#234;nese ou ao seu bloqueio: um, que promove a prolifera&#231;&#227;o e a sobreviv&#234;ncia atrav&#233;s de CE pela ativa&#231;&#227;o de receptores VEGF de sinaliza&#231;&#227;o e express&#227;o de eNOS e, outro, que inicia a apoptose. Os resultados podem depender da gravidade da hip&#243;xia. Hipoxemia moderada promove, principalmente, prolifera&#231;&#227;o e sobreviv&#234;ncia, enquanto hipoxemia grave, pr&#243;xima a condi&#231;&#245;es anaer&#243;bicas, pode causar apoptose significativa. <italic>In vivo</italic>, o ac&#250;mulo de FIH decorrente de apoptose de CE n&#227;o tem sido reportado<sup>6</sup>. </p>
    <p>
      <bold>2. C&#233;lulas musculares lisas vasculares</bold>
    </p>
    <p>Tal como ocorre com as c&#233;lulas endoteliais, a hipoxemia grave provoca apoptose das CML, enquanto a hipoxemia moderada aumenta sua prolifera&#231;&#227;o. Induzida por hip&#243;xia, a express&#227;o da ciclo-oxigenase (COX)-2 e FCDP-&#946; &#233; importante para os receptores de CML que estimulam sua prolifera&#231;&#227;o. O mecanismo preciso &#233; desconhecido, mas uma possibilidade &#233; que o MT1-MMP possa agir como uma mol&#233;cula acess&#243;ria da atividade proteol&#237;tica associada com receptor FCDP-&#946;<sup>45</sup>. </p>
    <p>
      <bold>3. Macr&#243;fagos</bold>
    </p>
    <p>Em resposta &#224; hipoxemia tecidual, um grande n&#250;mero de mon&#243;citos &#233; recrutado da circula&#231;&#227;o para os tecidos hip&#243;xicos, onde se diferenciam em macr&#243;fagos. V&#225;rios fatores e prote&#237;nas nos tecidos hip&#243;xicos contribuem para o recrutamento dos mon&#243;citos, a saber: prote&#237;na-1 (MCP-1), FNT-a, FEC-1, fator derivado estromal (FDE)-1 e VEGF-A. Os macr&#243;fagos promovem a angiog&#234;nese ao estimular a secre&#231;&#227;o de metaloproteinases da matriz (MMP) e uma variedade de fatores angiog&#234;nicos, tais como VEGF-A, FCF, interleucina-2 e fator de necrose tumoral. Al&#233;m disso, os macr&#243;fagos tamb&#233;m secretam um curto pept&#237;deo de 39 res&#237;duos de amino&#225;cidos (PR39), que podem facilmente atravessar a membrana plasm&#225;tica, entrar nas c&#233;lulas e inibir a degrada&#231;&#227;o do FIH-&#945;. Essa fun&#231;&#227;o do PR39 pode melhorar a capacidade das c&#233;lulas residentes dos tecidos hip&#243;xicos de secretar fatores angiog&#234;nicos, devido ao aumento da concentra&#231;&#227;o local de FIH-1<sup>6</sup>. </p>
    <p>Finalmente, tamb&#233;m os macr&#243;fagos respondem &#224; hipoxemia atrav&#233;s da produ&#231;&#227;o de uma prote&#237;na reguladora de oxig&#234;nio (PRO) pelo ret&#237;culo endoplasm&#225;tico e que promove a secre&#231;&#227;o de VEGF-A pelo mesmo ret&#237;culo endoplasm&#225;tico<sup>6</sup>. </p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>De forma geral, a angiog&#234;nese coron&#225;ria em adultos &#233;, fundamentalmente, uma resposta potente par&#225;crina da rede capilar preexistente em condi&#231;&#245;es fisiopatol&#243;gicas de isquemia e/ou de inflama&#231;&#227;o. A pesquisa b&#225;sica e o entendimento dos mecanismos s&#227;o necess&#225;rios, a fim de dar suporte &#224;s grandes lacunas no conhecimento e possibilitar a execu&#231;&#227;o de efetivas estrat&#233;gias no campo da terapia angiog&#234;nica coronariana. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p> Este artigo &#233; parte de tese de Doutorado de Gabriel Lorier pela IC/FUC.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Renato Abdala Karam Kalil </p>
        <p> Av. Princesa Isabel, 370 </p>
        <p> 90620-000 - Santana, Porto Alegre, RS, Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="kalil.pesquisa@cardiologia.org.br">kalil.pesquisa@cardiologia.org.br</email>, </p>
        <p>
          <email xlink:href="editoracao-pc@cardiologia.org.br">editoracao-pc@cardiologia.org.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 24/03/11; revisado recebido em 13/06/11; aceito em 04/07/11.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Kornowski R, Epstein SE, Leon MB. Handbook of myocardial revascularization and angiogenesis. London: Martin Dunitz Ltd; 1999.</mixed-citation>
        <element-citation publication-type="book">
          <source>Handbook of myocardial revascularization and angiogenesis</source>
          <date>
            <year>1999</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Kornowski</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Epstein</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Angiogenesis</article-title>
          <source>J Biol Chem</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>10931</fpage>
          <lpage>4</lpage>
          <issue>16</issue>
          <volume>267</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Folkman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shing</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Schaper W, Buschmann I. Arteriogenesis, the good and bad of it. Cardiovasc Res. 1999;43(4):835-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Arteriogenesis, the good and bad of it</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>835</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schaper</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Buschmann</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Isner JM. Angiogenesis. In: Topol EJ, ed. Textbook of cardiovascular medicine. Philadelphia: Lippincott Williams &amp; Wilkins; 1998. p. 2491-518.</mixed-citation>
        <element-citation publication-type="book">
          <source>Textbook of cardiovascular medicine</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>2491</fpage>
          <lpage>518</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Isner</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Topol</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Gottschall C. Fun&#231;&#227;o card&#237;aca: da normalidade &#224; insufici&#234;ncia. S&#227;o Paulo: BYK; 1995.</mixed-citation>
        <element-citation publication-type="book">
          <source>Fun&#231;&#227;o card&#237;aca: da normalidade &#224; insufici&#234;ncia</source>
          <date>
            <year>1995</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Gottschall</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9(6):677-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Regulation of angiogenesis by hypoxia: role of the HIF system</article-title>
          <source>Nat Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>677</fpage>
          <lpage>84</lpage>
          <issue>6</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pugh</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Ratcliffe</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7(4):430-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function</article-title>
          <source>Nat Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>430</fpage>
          <lpage>6</lpage>
          <issue>4</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kocher</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Schuster</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Szabolcs</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Takuma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Burkhoff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006;124(1):175-89.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells</article-title>
          <source>Cell</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>175</fpage>
          <lpage>89</lpage>
          <issue>1</issue>
          <volume>124</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grunewald</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Avraham</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dor</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Bachar-Lustig</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Itin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Vink A, Schoneveld AH, Lamers D, Houben AJ, van der Groep P, van Diest PJ, et al. HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis. 2007;195(2):e69-75.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages</article-title>
          <source>Atherosclerosis</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>e69</fpage>
          <lpage>75</lpage>
          <issue>2</issue>
          <volume>195</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vink</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schoneveld</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Lamers</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Houben</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>van der Groep</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>van Diest</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res. 1994;28(8):1176-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1176</fpage>
          <lpage>9</lpage>
          <issue>8</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Banai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shweiki</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pinson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chandra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lazarovici</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Keshet</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Semenza GL. Transcriptional regulation by hypoxia-inducible factor 1 molecular mechanisms of oxygen homeostasis. Trends Cardiovasc Med. 1996;6(5):151-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Transcriptional regulation by hypoxia-inducible factor 1 molecular mechanisms of oxygen homeostasis</article-title>
          <source>Trends Cardiovasc Med</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>151</fpage>
          <lpage>7</lpage>
          <issue>5</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Semenza</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanisms of angiogenesis</article-title>
          <source>Nature</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>671</fpage>
          <lpage>4</lpage>
          <issue>6626</issue>
          <volume>386</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Risau</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Henry TD. Can we really grow new blood vessels? Lancet. 1998;351(9119):1826-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Can we really grow new blood vessels</article-title>
          <source>Lancet</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1826</fpage>
          <lpage>7</lpage>
          <issue>9119</issue>
          <volume>351</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Henry</surname>
              <given-names>TD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1</article-title>
          <source>Nat Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>858</fpage>
          <lpage>64</lpage>
          <issue>8</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ceradini</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Callaghan</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Tepper</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Bastidas</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kleinman</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Kalka C, Tehrani H, Laudenberg B, Vale PR, Isner JM, Asahara T, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg. 2000;70(3):829-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>829</fpage>
          <lpage>34</lpage>
          <issue>3</issue>
          <volume>70</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kalka</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tehrani</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Laudenberg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vale</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Isner</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Asahara</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Kleinman ME, Greives MR, Churgin SS, Blechman KM, Chang EI, Ceradini DJ, et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol. 2007;27(12):2664-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2664</fpage>
          <lpage>70</lpage>
          <issue>12</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kleinman</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Greives</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Churgin</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Blechman</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>EI</given-names>
            </name>
            <name>
              <surname>Ceradini</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005;80(1):229-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>229</fpage>
          <lpage>36</lpage>
          <issue>1</issue>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ge</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107(9):1322-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1322</fpage>
          <lpage>8</lpage>
          <issue>9</issue>
          <volume>107</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yamaguchi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kusano</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Masuo</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Kawamoto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Silver</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murasawa</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Jo DY, Hwang JH, Kim JM, Yun HJ, Kim S. Human bone marrow endothelial cells elaborate non-stromal-cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of haematopoietic progenitors. Br J Haematol. 2003;121(4):649-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Human bone marrow endothelial cells elaborate non-stromal-cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of haematopoietic progenitors</article-title>
          <source>Br J Haematol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>649</fpage>
          <lpage>52</lpage>
          <issue>4</issue>
          <volume>121</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jo</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Yun</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004;110(21):3300-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>3300</fpage>
          <lpage>5</lpage>
          <issue>21</issue>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Abbott</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hickey</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Krause</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Giordano</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000;80(1):99-115.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor</article-title>
          <source>Lab Invest</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>99</fpage>
          <lpage>115</lpage>
          <issue>1</issue>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pettersson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nagy</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Sundberg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jungles</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107(8):1164-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1164</fpage>
          <lpage>9</lpage>
          <issue>8</issue>
          <volume>107</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rehman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Orschell</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>March</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood. 2009;114(3):723-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures</article-title>
          <source>Blood</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>723</fpage>
          <lpage>32</lpage>
          <issue>3</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Prokopi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pula</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mayr</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Devue</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Schmeisser A, Garlichs CD, Zhang H, Eskafi S, Graffy C, Ludwig J, et al. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res. 2001;49(3):671-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>671</fpage>
          <lpage>80</lpage>
          <issue>3</issue>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schmeisser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garlichs</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Eskafi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Graffy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res. 2004;94(2):230-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Bone marrow-derived cells do not incorporate into the adult growing vasculature</article-title>
          <source>Circ Res</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>230</fpage>
          <lpage>8</lpage>
          <issue>2</issue>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ziegelhoeffer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kostin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Heil</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Voswinckel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Helisch</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002;282(5):C947-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanisms of normal and tumor-derived angiogenesis</article-title>
          <source>Am J Physiol Cell Physiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>C947</fpage>
          <lpage>70</lpage>
          <issue>5</issue>
          <volume>282</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Papetti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Herman</surname>
              <given-names>IM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Adult cardiac stem cells are multipotent and support myocardial regeneration</article-title>
          <source>Cell</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>763</fpage>
          <lpage>76</lpage>
          <issue>6</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Beltrami</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Barlucchi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Torella</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Limana</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chimenti</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Linke A, Muller P, Nurzynska D, Casarsa C, Torella D, Nascimbene A, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci USA. 2005;102(25):8966-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>8966</fpage>
          <lpage>71</lpage>
          <issue>25</issue>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Linke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nurzynska</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Casarsa</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Torella</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nascimbene</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Angiogenesis as a therapeutic target</article-title>
          <source>Nature</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>967</fpage>
          <lpage>74</lpage>
          <issue>7070</issue>
          <volume>438</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferrara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kerbel</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The biology of vascular endothelial growth factor</article-title>
          <source>Endocr Rev</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>4</fpage>
          <lpage>25</lpage>
          <issue>1</issue>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferrara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Davis-Smyth</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The biology of VEGF and its receptors</article-title>
          <source>Nat Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>669</fpage>
          <lpage>76</lpage>
          <issue>6</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferrara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gerber</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>LeCouter</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanisms of angiogenesis and arteriogenesis</article-title>
          <source>Nat Med</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>389</fpage>
          <lpage>95</lpage>
          <issue>4</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carmeliet</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Taipale J, Makinen T, Arighi E, Kukk E, Karkkainen M, Alitalo K. Vascular endothelial growth factor receptor-3. Curr Top Microbiol Immunol. 1999;237:85-96.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular endothelial growth factor receptor-3</article-title>
          <source>Curr Top Microbiol Immunol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>85</fpage>
          <lpage>96</lpage>
          <volume>237</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taipale</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Makinen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Arighi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kukk</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Karkkainen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alitalo</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Hangai M, Kitaya N, Xu J, Chan CK, Kim JJ, Werb Z, et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol. 2002;161(4):1429-37.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis</article-title>
          <source>Am J Pathol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1429</fpage>
          <lpage>37</lpage>
          <issue>4</issue>
          <volume>161</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hangai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kitaya</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Werb</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Carmeliet P. Developmental biology: controlling the cellular brakes. Nature. 1999;401(6754):657-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Developmental biology: controlling the cellular brakes</article-title>
          <source>Nature</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>657</fpage>
          <lpage>8</lpage>
          <issue>6754</issue>
          <volume>401</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carmeliet</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Carmeliet P. Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis? Circ Res. 2000;87(3):176-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis?</article-title>
          <source>Circ Res</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>176</fpage>
          <lpage>8</lpage>
          <issue>3</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carmeliet</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost. 2001;86(1):346-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Extracellular proteolysis and angiogenesis</article-title>
          <source>Thromb Haemost</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>346</fpage>
          <lpage>55</lpage>
          <issue>1</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pepper</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Luttun A, Dewerchin M, Collen D, Carmeliet P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr Atheroscler Rep. 2000;2(5):407-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies</article-title>
          <source>Curr Atheroscler Rep</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>407</fpage>
          <lpage>16</lpage>
          <issue>5</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Luttun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dewerchin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Collen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Carmeliet</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Isner JM, Takayuki A. Therapeutic angiogenesis. Front Biosci. 1998;3:e49-69.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Therapeutic angiogenesis</article-title>
          <source>Front Biosci</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>e49</fpage>
          <lpage>69</lpage>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Isner</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Takayuki</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Werdich XQ, Penn JS. Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events. Angiogenesis. 2005;8(4):315-26.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events</article-title>
          <source>Angiogenesis</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>315</fpage>
          <lpage>26</lpage>
          <issue>4</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Werdich</surname>
              <given-names>XQ</given-names>
            </name>
            <name>
              <surname>Penn</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Ozerdem U, Stallcup WB. Early contribution of pericytes to angiogenic sprouting and tube formation. Angiogenesis. 2003;6(3):241-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Early contribution of pericytes to angiogenic sprouting and tube formation</article-title>
          <source>Angiogenesis</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>241</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ozerdem</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Stallcup</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Tomanek RJ. Formation of the coronary vasculature during development. Angiogenesis. 2005;8(3):273-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Formation of the coronary vasculature during development</article-title>
          <source>Angiogenesis</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>273</fpage>
          <lpage>84</lpage>
          <issue>3</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tomanek</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002;8(9):918-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A reevaluation of integrins as regulators of angiogenesis</article-title>
          <source>Nat Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>918</fpage>
          <lpage>21</lpage>
          <issue>9</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hynes</surname>
              <given-names>RO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80(4):1669-99.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of platelet-activating factor in cardiovascular pathophysiology</article-title>
          <source>Physiol Rev</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1669</fpage>
          <lpage>99</lpage>
          <issue>4</issue>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Montrucchio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Alloatti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Camussi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83(3):835-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Regulation of wound healing by growth factors and cytokines</article-title>
          <source>Physiol Rev</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>835</fpage>
          <lpage>70</lpage>
          <issue>3</issue>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Werner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grose</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9(6):685-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Molecular regulation of vessel maturation</article-title>
          <source>Nat Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>685</fpage>
          <lpage>93</lpage>
          <issue>6</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jain</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol. 1994;267(4 Pt 2):H1263-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb</article-title>
          <source>Am J Physiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>H1263</fpage>
          <lpage>71</lpage>
          <issue>4</issue>
          <volume>267</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bauters</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Asahara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Takeshita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bunting</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ferrara</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96(5):2260-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty</article-title>
          <source>J Clin Invest</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>2260</fpage>
          <lpage>8</lpage>
          <issue>5</issue>
          <volume>96</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Barr</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Leiden</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation. 1995;91(11):2687-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease</article-title>
          <source>Circulation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>2687</fpage>
          <lpage>92</lpage>
          <issue>11</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Isner</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Symes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pieczek</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Takeshita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lowry</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B50">
        <mixed-citation>50. Yacyshyn OK, Lai PF, Forse K, Teichert-Kuliszewska K, Jurasz P, Stewart DJ. Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells. Angiogenesis. 2009;12(1):25-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells</article-title>
          <source>Angiogenesis</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>25</fpage>
          <lpage>33</lpage>
          <issue>1</issue>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yacyshyn</surname>
              <given-names>OK</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Forse</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Teichert-Kuliszewska</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jurasz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B51">
        <mixed-citation>51. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998;97(1):99-107.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>99</fpage>
          <lpage>107</lpage>
          <issue>1</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Murohara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Horowitz</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Silver</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsurumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B52">
        <mixed-citation>52.  van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothellium. Circulation. 1997;95(4):1030-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothellium</article-title>
          <source>Circulation</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1030</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>van der Zee</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Murohara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zollmann</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Passeri</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lekutat</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B53">
        <mixed-citation>53. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11(2):109-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular permeability, vascular hyperpermeability and angiogenesis</article-title>
          <source>Angiogenesis</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>109</fpage>
          <lpage>19</lpage>
          <issue>2</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nagy</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dvorak</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Dvorak</surname>
              <given-names>HF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Angiog&#233;nesis coronaria como respuesta end&#243;gena de la isquemia mioc&#225;rdica en el adulto</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>El proceso de angiog&#233;nesis involucra una serie compleja de est&#237;mulos y de respuestas integradas, como la estimulaci&#243;n de las c&#233;lulas endoteliales (CE), para su proliferaci&#243;n y migraci&#243;n, estimulaci&#243;n de la matriz extracelular, para la atracci&#243;n de pericitos y macr&#243;fagos, estimulaci&#243;n de las c&#233;lulas musculares lisas, para su proliferaci&#243;n y migraci&#243;n, y formaci&#243;n de nuevas estructuras vasculares. La angiog&#233;nesis es principalmente una respuesta adaptativa a la hipoxia tisular y depende de la acumulaci&#243;n del factor de crecimiento inducido por la hipoxia (FIH-1 &#945;) en la zona del miocardio isqu&#233;mico, que sirve para aumentar la transcripci&#243;n del factor de crecimiento endotelial vascular (con sus siglas en ingl&#233;s: VEGF vascular endotelial growth factor), y sus receptores VEGF-R, por las CE en el sufrimiento isqu&#233;mico. Esos pasos aglutinan mecanismos enzim&#225;ticos y proteasas activadoras del plasmin&#243;geno, metaloproteinasas (MMP) de la matriz extracelular (MEC), y cinasas que provocan la degradaci&#243;n molecular proteol&#237;tica de la MEC, como tambi&#233;n la activaci&#243;n y la liberaci&#243;n de factores de crecimiento, tales como: factor b&#225;sico de crecimiento de los fibroblastos (FCFb), VEGF y factor de crecimiento insul&#237;nico-1 (FCI-1). Posteriormente, viene la fase intermedia de estabilizaci&#243;n del nuevo brote neovascular inmaduro y la fase final de maduraci&#243;n vascular de la angiog&#233;nesis fisiol&#243;gica. Como conclusiones generales, podemos afirmar que la angiog&#233;nesis coronaria en adultos es fundamentalmente, una respuesta paracrina de la red capilar preexistente en condiciones fisiopatol&#243;gicas de isquemia e inflamaci&#243;n.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Isquemia mioc&#225;rdica</kwd>
        <kwd>neovascularizaci&#243;n fisiol&#243;gica</kwd>
        <kwd>c&#233;lulas endoteliales</kwd>
        <kwd>adulto</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ACTUALIZACI&#211;N CL&#205;NICA</bold>
      </p>
      <p>
        <fn id="enda-body2">
          <label>
            <bold>Angiog&#233;nesis coronaria como respuesta end&#243;gena de la isquemia mioc&#225;rdica en el adulto</bold>
          </label>
          <p>
            <bold>Gabriel Lorier<sup>I</sup>; Cristina Touri&#241;o<sup>I</sup>; Renato A. K. Kalil<sup>II,III</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Universidad de La Republica, Montevideo, Uruguay (UDELAR); Porto Alegre, Rio Grande do Sul, Brasil</p>
      <p><sup>II</sup>Instituto de Cardiologia do Rio Grande do Sul - Funda&#231;&#227;o Universit&#225;ria de Cardiologia - (IC/FUC); Porto Alegre, Rio Grande do Sul, Brasil </p>
      <p><sup>III</sup>Universidade Federal de Ci&#234;ncias da Sa&#250;de de Porto Alegre - (UFCSPA), Porto Alegre, Rio Grande do Sul, Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>El proceso de angiog&#233;nesis involucra una serie compleja de est&#237;mulos y de respuestas integradas, como la estimulaci&#243;n de las c&#233;lulas endoteliales (CE), para su proliferaci&#243;n y migraci&#243;n, estimulaci&#243;n de la matriz extracelular, para la atracci&#243;n de pericitos y macr&#243;fagos, estimulaci&#243;n de las c&#233;lulas musculares lisas, para su proliferaci&#243;n y migraci&#243;n, y formaci&#243;n de nuevas estructuras vasculares.</p>
      <p> La angiog&#233;nesis es principalmente una respuesta adaptativa a la hipoxia tisular y depende de la acumulaci&#243;n del factor de crecimiento inducido por la hipoxia (FIH-1 &#945;) en la zona del miocardio isqu&#233;mico, que sirve para aumentar la transcripci&#243;n del factor de crecimiento endotelial vascular (con sus siglas en ingl&#233;s: VEGF <italic>vascular endotelial growth factor</italic>), y sus receptores VEGF-R, por las CE en el sufrimiento isqu&#233;mico.</p>
      <p> Esos pasos aglutinan mecanismos enzim&#225;ticos y proteasas activadoras del plasmin&#243;geno, metaloproteinasas (MMP) de la matriz extracelular (MEC), y cinasas que provocan la degradaci&#243;n molecular proteol&#237;tica de la MEC, como tambi&#233;n la activaci&#243;n y la liberaci&#243;n de factores de crecimiento, tales como: factor b&#225;sico de crecimiento de los fibroblastos (FCFb), VEGF y factor de crecimiento insul&#237;nico-1 (FCI-1). Posteriormente, viene la fase intermedia de estabilizaci&#243;n del nuevo brote neovascular inmaduro y la fase final de maduraci&#243;n vascular de la angiog&#233;nesis fisiol&#243;gica.</p>
      <p> Como conclusiones generales, podemos afirmar que la angiog&#233;nesis coronaria en adultos es fundamentalmente, una respuesta paracrina de la red capilar preexistente en condiciones fisiopatol&#243;gicas de isquemia e inflamaci&#243;n.</p>
      <p><bold>Palabras clave:</bold> Isquemia mioc&#225;rdica, neovascularizaci&#243;n fisiol&#243;gica, c&#233;lulas endoteliales, adulto.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>En esta revisi&#243;n, traemos a colaci&#243;n la angiog&#233;nesis mioc&#225;rdica end&#243;gena en el adulto, bajo un prisma unificado de los diversos mecanismos moleculares ya descritos. Esa visi&#243;n se basa en la interpretaci&#243;n "din&#225;mica" de la definici&#243;n refrendada por Folkman: "La angiog&#233;nesis es la generaci&#243;n y la expansi&#243;n de los vasos sangu&#237;neos a partir de una red vascular preexistente, bajo est&#237;mulos end&#243;genos o ex&#243;genos"<sup>1</sup>. En el adulto, la angiog&#233;nesis es en gran medida, una respuesta adaptativa a la hipoxia tisular y ocurre en una amplia variedad de situaciones, que van desde el desarrollo embrionario hasta el crecimiento tumoral<sup>2</sup>. </p>
      <p>Como mediador de la cascada de eventos celulares y moleculares, est&#225; la activaci&#243;n del FIH- 1, que sirve para aumentar la transcripci&#243;n por las CE, en el sufrimiento isqu&#233;mico, del VEGF y sus receptores VEGF-R<sup>3</sup>. </p>
      <p>Creemos que la red capilar preexistente es el lugar de inicio com&#250;n para el desarrollo y la generaci&#243;n de los nuevos capilares, intermediada por los diferentes sistemas de signos que desencadenan la producci&#243;n de factores de crecimiento y que terminan induciendo a la proliferaci&#243;n de las c&#233;lulas endoteliales. La definici&#243;n de angiog&#233;nesis hecha por Folkman, ya citada, se basa en s&#243;lidos elementos an&#225;tomo-morfom&#233;tricos.</p>
      <p>La relaci&#243;n capilar/fibra mioc&#225;rdica normal en el coraz&#243;n del adulto es de 1 para 1, o sea, un capilar por fibra mioc&#225;rdica. El calibre m&#225;ximo de nuevos vasos identificados en el proceso de angiog&#233;nesis es de 200 &#181;m de di&#225;metro<sup>4</sup>. Si no hay una circulaci&#243;n coronaria epic&#225;rdica de alimentaci&#243;n de esa circulaci&#243;n colateral con un flujo sangu&#237;neo adecuado, es posible que ocurra la regresi&#243;n paulatina del proceso de angiog&#233;nesis. A su vez, cada fibra del miocardio tiene un di&#225;metro que var&#237;a de 10 a 25 &#181;m y su largura tambi&#233;n var&#237;a de 50 a 100 &#181;m, con una distribuci&#243;n capilar uniforme en la pared ventricular izquierda de 3.000 para 4.000/cm<sup>2 5</sup>. </p>
      <p>Por tanto, podemos decir que esa definici&#243;n posee una fuerte sustentaci&#243;n morfom&#233;trica. Eso significa que, en el coraz&#243;n adulto normal en reposo, para que se mantenga la vida celular, debe existir una fuente de nutrientes para el coraz&#243;n. En otras palabras, las c&#233;lulas progenitoras endoteliales circulantes (CPEc), necesitan una circulaci&#243;n coronaria preexistente para llegar a la regi&#243;n en que ocurre la isquemia mioc&#225;rdica.</p>
      <p>Al analizar el segundo componente de la definici&#243;n de Folkman, cuando dice: "[...] por est&#237;mulos end&#243;genos o ex&#243;genos...", verificamos que se extendi&#243; a los dos principales mecanismos del proceso de la angiog&#233;nesis: la end&#243;gena son los procesos fisiol&#243;gicos y patol&#243;gicos, mientras que la ex&#243;gena es la terapia angiog&#233;nica cardiovascular como forma ex&#243;gena de inducci&#243;n de la angiog&#233;nesis. El objetivo de esta revisi&#243;n es analizar los mecanismos de la angiog&#233;nesis end&#243;gena en los procesos fisiol&#243;gicos.</p>
      <p>
        <bold>I. Fases de la Regulaci&#243;n de los Mecanismos Inductores de la Angiog&#233;nesis Mioc&#225;rdica End&#243;gena en el Adulto:</bold>
      </p>
      <p>
        <bold>1. Fase inicial: isquemia mioc&#225;rdica como est&#237;mulo inicial</bold>
      </p>
      <p>La angiog&#233;nesis es principalmente, una respuesta adaptativa a la hipoxia tisular y depende de la acumulaci&#243;n de FIH-1 &#945;, que, en condiciones de hipoxia tisular, activa la expresi&#243;n de factores de crecimiento e inicia el proceso de angiog&#233;nesis en la regi&#243;n isqu&#233;mica a partir de la red coronaria preexistente<sup>6</sup>. Adem&#225;s, la atracci&#243;n y el reclutamiento de CPEc y de macr&#243;fagos activan, de forma paracrina, la angiog&#233;nesis en esa regi&#243;n<sup>7</sup>. La expresi&#243;n del VEGF-A es un indicativo del reclutamiento de los progenitores mieloides en el miocardio isqu&#233;mico, mientras que las c&#233;lulas perivasculares de la angiog&#233;nesis est&#225;n intermediadas por los factores derivados de las c&#233;lulas estromales (FDE)-1 (<xref ref-type="fig" rid="es_a19fig01m-body2">Figura 1</xref>)<sup>8</sup>. </p>
      <p content-type="asset">
        <fig id="es_a19fig01m-body2">
          <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf01-es.jpg"/></fig>
      </p>
      <p>En la cardiopat&#237;a isqu&#233;mica, tanto FIH-1&#945; como VEGF-A, est&#225;n presentes en la placa arterioscler&#243;tica, lo que indica que el FIH, por v&#237;a de la se&#241;alizaci&#243;n angiog&#233;nica, est&#225; directamente involucrado en el crecimiento de la placa arterioscler&#243;tica<sup>9</sup>. </p>
      <p>La isquemia mioc&#225;rdica grave conlleva a la acumulaci&#243;n de FIH-1 y a la expresi&#243;n de factores que estimulan brotes angiog&#233;nicos en las cercan&#237;as de los vasos sangu&#237;neos en el miocardio isqu&#233;mico. No nos podemos olvidar que la isquemia grave y persistente causa apoptosis de la CE y de las fibras mioc&#225;rdicas. Adem&#225;s, los progenitores mieloides y endoteliales derivados de la m&#233;dula &#243;sea tambi&#233;n son reclutados para participar activamente en el apoyo a la angiog&#233;nesis<sup>10</sup>. </p>
      <p>El FIH-1&#945; es muy importante para la angiog&#233;nesis en el miocardio. Sin embargo, poco se sabe respecto del FIH-2&#945;. Los cardiomiocitos privados de FIH-1&#945; espec&#237;ficos fueron llevados a la reducci&#243;n de la vascularizaci&#243;n, alteraciones en el metabolismo energ&#233;tico y anormalidad de la funci&#243;n contr&#225;ctil. En contrapartida, la superexpresi&#243;n de la prote&#237;na de fusi&#243;n FIH-1&#945;/VP16 (FIH-1&#945; del ADN vinculante y activador de dominio vinculado con la heterodimerizaci&#243;n VP16), fue capaz de promover la angiog&#233;nesis y de reducir el tama&#241;o del infarto en un modelo experimental en ratones. Tal como ocurre en otros tejidos hip&#243;xicos, el FIH-1&#945; es esencial para el aumento de la concentraci&#243;n en la m&#233;dula &#243;sea, de los precursores de CE. Incluso una deficiencia parcial de FIH-1&#945;, proveniente del envejecimiento, est&#225; asociada a una reducci&#243;n significativa de la concentraci&#243;n de esas c&#233;lulas, y a una vascularizaci&#243;n pobre en el m&#250;sculo isqu&#233;mico<sup>11</sup>. </p>
      <p>La hipoxemia tambi&#233;n regula la producci&#243;n y la expresi&#243;n del VEGF, en raz&#243;n del aumento de la transcripci&#243;n del FIH-1 y del aumento en la estabilidad del VEGF-dependiente de la regi&#243;n 3 del ARNm<sup>11</sup>. </p>
      <p>El mecanismo molecular iniciador de la angiog&#233;nesis puede ser impulsado por la privaci&#243;n de ox&#237;geno y de los nutrientes, como la glucosa, que regulan la expresi&#243;n g&#233;nica. Tambi&#233;n observamos, que la hipoxia regula los receptores TIE-2, siendo moduladores de la actividad del VEGF, lo que conlleva las CE a proliferar por los mecanismos de brote o divisi&#243;n. De acuerdo con el est&#225;ndar del signo del VEGF y TIE-2, se puede inducir la angiog&#233;nesis por brotes o intususcepci&#243;n<sup>12</sup>. Un hecho importante, de aplicaci&#243;n terap&#233;utica del VEGF, es que la isquemia estimula su expresi&#243;n, como tambi&#233;n la de sus receptores<sup>13</sup> (<xref ref-type="fig" rid="es_a19fig01m-body2">Figura 1</xref>).</p>
      <p>
        <bold>1.1. Mecanismo de angiog&#233;nesis por atracci&#243;n de c&#233;lulas-tronco circulantes durante el infarto agudo del miocardio</bold>
      </p>
      <p>Durante la isquemia mioc&#225;rdica, el aumento de la expresi&#243;n y estabilizaci&#243;n de la transcripci&#243;n de FIH-1, genera una producci&#243;n local y la liberaci&#243;n por la CE en el sufrimiento isqu&#233;mico de los factores FDE-1 y VEGF-A<sup>14</sup>. El FIH circulante regula muchos genes de la angiog&#233;nesis, pero la inducci&#243;n del VEGF tal vez sea lo que m&#225;s notamos. FIH aumenta la concentraci&#243;n local de VEGF en hasta 30 veces en pocos minutos. El VEGF estimula la angiog&#233;nesis fisiol&#243;gica y patol&#243;gica en una respuesta estricta de dosis-dependente<sup>6</sup>. Esos mediadores pueden aumentar la movilizaci&#243;n y el reclutamiento de las CPEc en el &#225;rea isqu&#233;mica<sup>15</sup>. </p>
      <p>El aumento de la expresi&#243;n de FDE-1 es esencial para la regulaci&#243;n de la atracci&#243;n, migraci&#243;n y retenci&#243;n selectiva en el tejido mioc&#225;rdico isqu&#233;mico, de las CPEc o de las CE, con el receptor de superficie 4 de la quemoquina CXC-R4<sup>16</sup>. Eso significa que la v&#237;a FIH-1 es el mecanismo de unificaci&#243;n del sistema de se&#241;alizaci&#243;n de la angiog&#233;nesis en el contexto del infarto agudo del miocardio (<xref ref-type="fig" rid="es_a19fig01m-body2">Figura 1</xref>).</p>
      <p>Esas CPEc, del mismo modo que ocurre con las c&#233;lulas mesenquimales de la m&#233;dula &#243;sea (entre otras), son movilizadas, atra&#237;das y desplazadas de la circulaci&#243;n perif&#233;rica hacia las &#225;reas de isquemia mioc&#225;rdica<sup>17</sup>. </p>
      <p>Existen pruebas de que FDE-1 con el receptor de se&#241;al CXC-R4 + desempe&#241;a un rol importante en el reclutamiento de c&#233;lulas circulantes de la m&#233;dula &#243;sea en el contexto de una grave isquemia mioc&#225;rdica. Esa se&#241;al es esencial para el reclutamiento de c&#233;lulas-tronco en el coraz&#243;n. El CXC-R4 + es un receptor de superficie celular de la FDE-1, expresado en las CPEc y en las c&#233;lulas-tronco circulantes hematopo&#233;ticas (CTHc)<sup>18</sup>. </p>
      <p>Las CPEc desempe&#241;an un papel importante en el mantenimiento de la pared vascular endotelial, auxiliando en la reendotelizaci&#243;n (cambio fisiol&#243;gico de las CE), y en la angiog&#233;nesis<sup>19</sup>. </p>
      <p>Pero los niveles de FDE-1 end&#243;geno segregado, se reducen despu&#233;s del IAM y vuelven al nivel normal despu&#233;s del 4&#186; &#243; 7&#186; d&#237;as del IAM<sup>20</sup>. </p>
      <p>Las c&#233;lulas mesenquimales circulantes derivadas de la m&#233;dula &#243;sea (CMcDMO), son un puente hacia el interior del miocardio isqu&#233;mico, expresado por el FDE-1, que podr&#225; ser una se&#241;al que facilite la migraci&#243;n de las c&#233;lulas circulantes y de la m&#233;dula &#243;sea<sup>17</sup>. </p>
      <p>Antes se cre&#237;a que los precursores endoteliales exist&#237;an solo durante la vida embrionaria. Actualmente, ya se han identificado precursores en la m&#233;dula &#243;sea y en los vasos perif&#233;ricos en el adulto. Algunos factores de crecimiento, como el factor estimulador de colonias de granulocitos (FECG), b-FCF y FCI-1, estimulan su diferenciaci&#243;n y su movilizaci&#243;n<sup>21</sup>. Esos precursores de c&#233;lulas endoteliales colonizan nuevas &#225;reas de brotes angiog&#233;nicos en el adulto, y en el futuro, pueden ser objetos terap&#233;uticos.</p>
      <p>Rehman et al<sup>22</sup> han cuestionado el origen de esas CPEc y su verdadera incorporaci&#243;n en la pared de los vasos en crecimiento. Ellos descubrieron que la mayor parte de las llamadas CPEc deriva de monocitos/macr&#243;fagos, con una peque&#241;a poblaci&#243;n de c&#233;lulas-tronco CD-34<sup>+</sup>/c&#233;lulas progenitoras hematopo&#233;ticas solamente, a partir de c&#233;lulas tronco/angioblastos. Esos monocitos/macr&#243;fagos segregan m&#250;ltiples factores de crecimiento angiog&#233;nicos, que a su vez tambi&#233;n generan, con su estimulaci&#243;n paracrina, el crecimiento neovascular<sup>22</sup>. </p>
      <p>El concepto de CPEc es muy interesante, aunque m&#225;s de una d&#233;cada despu&#233;s de su descubrimiento, a&#250;n no hay marcadores espec&#237;ficos de las CPEc y los resultados de los ensayos cl&#237;nicos todav&#237;a son controvertidos. Usando un enfoque prote&#243;mico, un reciente estudio muestra que las c&#233;lulas con fenotipo de CPEc podr&#237;an ser c&#233;lulas mononucleares circulantes con la incorporaci&#243;n de micropart&#237;culas de plaquetas<sup>23</sup>. </p>
      <p>Schmeisser et al<sup>24</sup> demostraron que el monocito CD-34<sup>+</sup> puede desarrollar <italic>in vitro</italic> un fenotipo endotelial y tomar forma en una estructura tubular, lo que indica un potencial papel de los monocitos en la angiog&#233;nesis<sup>24</sup>. </p>
      <p>Finalmente, Ziegelhoeffer et al<sup>25</sup> publicaron un estudio que nos conduce a la conclusi&#243;n de que, en el organismo adulto, las c&#233;lulas-tronco provenientes de la m&#233;dula &#243;sea no generan un crecimiento vascular por la incorporaci&#243;n en las paredes vasculares, pero s&#237; que lo hacen a trav&#233;s de m&#250;ltiples efectos paracrinos de citocinas angiog&#233;nicas<sup>25</sup>. </p>
      <p>En resumen, la angiog&#233;nesis es un mecanismo fisiol&#243;gico organizado bajo una restringida regulaci&#243;n, con muchos factores que influyen en el proceso activo a nivel molecular, incluyendo diversos polip&#233;ptidos solubles, como VEGF, angiopoietina, FCF, factores de crecimiento derivado de plaquetas (FCDP), factor de crecimiento transformador &#946; (FCT-&#946;), factor de necrosis tumoral (FNT)-&#945;, FECG, entre muchos outros<sup>26</sup>. </p>
      <p>
        <bold>1.2. Mecanismo de la angiog&#233;nesis end&#243;gena por activaci&#243;n de c&#233;lulas-tronco residentes en el coraz&#243;n</bold>
      </p>
      <p>El verdadero papel de ese mecanismo y de la cuantificaci&#243;n de su efecto angiog&#233;nico no se conoce a ciencia cierta. Las c&#233;lulas-tronco residentes en el miocardio (CTRM), fueron capaces de diferenciarse en los cardiomiocitos, c&#233;lulas endoteliales y c&#233;lulas musculares lisas<sup>27</sup>. Esas CTRMs expresan receptores para FCH y para FCI-1, que pueden conllevar al reclutamiento y a la proliferaci&#243;n de las CE y reponer algunas funciones del coraz&#243;n que han sufrido da&#241;o isqu&#233;mico. De la misma forma ocurre con las c&#233;lulas mesenquimales circulantes (MSCc), que son capaces de segregar FCH y FCI-1 en respuesta a la lesi&#243;n<sup>28</sup>. </p>
      <p>
        <bold>1.3. Proliferaci&#243;n de c&#233;lulas endoteliales como respuesta final com&#250;n de la isquemia mioc&#225;rdica: generaci&#243;n de brote vascular angiog&#233;nico</bold>
      </p>
      <p>En los adultos, ese proceso se debe, principalmente, a la hipoxemia, y se encuentra intermediado por la activaci&#243;n de FIH-1 a, que sirve para aumentar la transcripci&#243;n del VEG F y de sus receptores VEGFRs <sup>2</sup>. </p>
      <p>El VEG F estimula la angiog&#233;nesis fisiol&#243;gica y patol&#243;gica en una estricta relaci&#243;n dosis dependente<sup>29</sup>. El VEG F es una prote&#237;na que tiene la caracter&#237;stica espec&#237;fica de estimular la replicaci&#243;n de c&#233;lulas endoteliales vasculares, esenciales para la angiog&#233;nesis<sup>30</sup>. El VEGF-A se conecta a dos receptores tirosina-quinasa (RTK), VEGFR-1 (flt-1) y VEGFR-2 (KDR, Flk-1). Los receptores tirosina-quinasa flt-1 (VEGF-R1), constituyen la segunda mayor afinidad para el VEGF. Aunque no sea tan espec&#237;fico, el receptor flk-1 no comparte las afinidades con las c&#233;lulas del sistema inflamatorio, como por ejemplo, monocitos o c&#233;lulas cancerosas, al contrario del receptorjlt -1 . En un reciente y elegante trabajo de la Universidad de Leuven, se hizo un importante descubrimiento con implicaciones terap&#233;uticas para el futuro, sea cual sea, la relativa especificidad del VEGF-B en t&#233;rminos de su actividad angiog&#233;nica en el tejido mioc&#225;rdico isqu&#233;mico<sup>31</sup>. </p>
      <p>En el mecanismo de la angiog&#233;nesis, debido al crecimiento vascular en forma de brote vascular, es posible determinar los siguientes pasos de manera simplificada: </p>
      <p>a) vasodilataci&#243;n inicial, proceso que envuelve el &#243;xido n&#237;trico y VEGF <sup>32</sup>; </p>
      <p>b) aumento de la permeabilidad vascular en respuesta al VEGF, como extravasaci&#243;n de prote&#237;nas plasm&#225;ticas que funcionan como un soporte para la migraci&#243;n de las c&#233;lulas endoteliales (CE). El aumento de la permeabilidad es producido por la formaci&#243;n de fenestraciones &#243;rgano-vesiculares y por la redistribuci&#243;n de las mol&#233;culas de adhesi&#243;n celular endotelial plaquetaria<sup>33</sup>; </p>
      <p>c) degradaci&#243;n proteol&#237;tica de la MEC : las proteinasas exponen prote&#237;nas de la ME C degradada, como col&#225;geno IV y mon&#243;mero de col&#225;geno fibrilar, que inducen a la migraci&#243;n de CE y CML<sup>34</sup>. </p>
      <p>Los tres pasos descritos envuelven mecanismos enzim&#225;ticos que incluyen la Ang2, un inhibidor de TIE2 <sup>35</sup>, proteasas activadoras del plasmin&#243;geno, metaloproteinasas (MMP) de la MEC , y cinasas o familia de las heparinasas. </p>
      <p>Todas as proteasas influyen en la angiog&#233;nesis a trav&#233;s de la degradaci&#243;n molecular proteol&#237;tica de la MEC , y de la activaci&#243;n y liberaci&#243;n del factor de crecimiento, como bFCF, VEG F y IGF1 , secuestrado en la matriz extracelular (Cuadro 8 en la <xref ref-type="fig" rid="es_a19fig02m-body2">Figura 2</xref>)<sup>36</sup>. Tambi&#233;n ejercen una acci&#243;n proteol&#237;tica o factor de crecimiento transformador (FCT), y la activaci&#243;n proteol&#237;tica de quimioquinas angiog&#233;nicas como el IL-1. O sea, que durante la remodelaci&#243;n vascular por brotaci&#243;n, ocurre la degradaci&#243;n proteol&#237;tica, incluyendo los activadores de plasmin&#243;geno como la urocinasa activadora del plamin&#243;geno (UPA) y su inhibidor PAI-1, matriz metaloproteinasas (MMPs) e inhibidores de la metaloproteinasas de los tejidos (TIMPs), heparinasas, quinasas, tirosinasas y cadherinasas<sup>37</sup>. </p>
      <p content-type="asset">
        <fig id="es_a19fig02m-body2">
          <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf02-es.jpg"/></fig>
      </p>
      <p>Al analizar el papel cr&#237;tico de la degradaci&#243;n proteol&#237;tica de la ME C en el crecimiento y en el mantenimiento del brote angiog&#233;nico, deben ser considerados los l&#237;mites de tiempo de ese proceso. El proceso tambi&#233;n debe ser equilibrado, porque una degradaci&#243;n insuficiente impide que las c&#233;lulas vasculares dejen sus posiciones originales. Por otro lado, la excesiva degradaci&#243;n trunca el apoyo y la orientaci&#243;n para la migraci&#243;n de las CE y por ende, tambi&#233;n la angiog&#233;nesis<sup>38</sup>. </p>
      <p>En el proceso de la angiog&#233;nesis, una vez producida la degradaci&#243;n proteol&#237;tica de la MEC , seguida por la fragmentaci&#243;n de la membrana basal, se produce la migraci&#243;n quimiot&#225;ctica de las c&#233;lulas endoteliales a trav&#233;s de la membrana basal. Para que eso ocurra, se hace necesario que las conexiones intercelulares endoteliales est&#233;n degradadas. Cuando las CE migran para formar nuevos brotes, la ME C sufre una degradaci&#243;n proteol&#237;tica y cambios en su composici&#243;n (<xref ref-type="fig" rid="es_a19fig03m-body2">Figura 3</xref>). </p>
      <p content-type="asset">
        <fig id="es_a19fig03m-body2">
          <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf03-es.jpg"/></fig>
      </p>
      <p>La migraci&#243;n de las CE ocurre 24 horas antes de los siguientes procesos: </p>
      <p>a) proliferaci&#243;n; </p>
      <p>b) adhesi&#243;n y reestablecimento de contactos intracelulares;</p>
      <p> c) formaci&#243;n del lumen vascular;</p>
      <p> d) maduraci&#243;n funcional del endotelio. </p>
      <p>Como se puede apreciar, las proteasas desempe&#241;an un rol cr&#237;tico en el proceso de la angiog&#233;nesis<sup>39</sup>. La estimulaci&#243;n del VEG F sobre los receptores de la membrana tirosina-quinasa de las c&#233;lulas endoteliales vasculares, se expresa a trav&#233;s de miembros de genes Src de la familia de las tirisinaquinasa, como el Src, Fyn, Yes, que regulan m&#250;ltiples funciones intracelulares. En primer lugar, el Src, Fyn y Yes desempe&#241;an cada uno, un papel &#250;nico en el sistema de se&#241;alizaci&#243;n mitog&#233;nica del VEGF. En segundo lugar, contribuyen para la modulaci&#243;n del VEGF en la migraci&#243;n celular. En tercer lugar, Fyn desempe&#241;a un papel &#250;nico en la inducci&#243;n de VEG F para la formaci&#243;n del tubo neovascular. El Fyn tiene un efecto regulador negativo sobre la migraci&#243;n y la estabilizaci&#243;n del tubo neovascular inducido por el VEGF. Esos resultados suministran pruebas directas de que Src, Fyn y Yes tienen un importante papel en la regulaci&#243;n del VEG F en los eventos intermediados por las c&#233;lulas endoteliales<sup>40</sup>. </p>
      <p>La existencia de tubos con pericitos refleja el r&#225;pido inicio de la participaci&#243;n del pericito en la angiog&#233;nesis intususceptiva (ver Cuadro 4 de la <xref ref-type="fig" rid="es_a19fig02m-body2">Figura 2</xref>). La creaci&#243;n de una red vascular funcional exige que los brotes vasculares emergentes maduren y permanezcan funcionales a lo largo del tiempo. La asociaci&#243;n del pericito y del CML con los brotes de reciente formaci&#243;n de las CE, regula su proliferaci&#243;n, supervivencia, migraci&#243;n, diferenciaci&#243;n, ramificaci&#243;n vascular, flujo sangu&#237;neo y permeabilidad vascular. La participaci&#243;n r&#225;pida de los pericitos en el desarrollo de la microvasculatura tiene importantes implicaciones para la intervenci&#243;n terap&#233;utica en muchas enfermedades<sup>41</sup>. </p>
      <p>El flujo sangu&#237;neo, con su presi&#243;n sobre la nueva pared vascular, interact&#250;a de forma integrada y din&#225;mica con el citoesqueleto y la MEC . El flujo sangu&#237;neo continuo estimula la proliferaci&#243;n de las c&#233;lulas endoteliales y regula el VEGF, integrina aVb3, PECAM-1 y VE-cadherina. La tensi&#243;n de cizallamiento <italic>{"shearstress"),</italic> estimula la proliferaci&#243;n de las c&#233;lulas endoteliales y por ende, aumenta el di&#225;metro del vaso<sup>42</sup>. </p>
      <p>La ME C suministra los contactos necesarios entre las CE y los tejidos circundantes, impidiendo que los brotes neovasculares se degeneren. Una matriz de col&#225;geno intersticial y elastina entre las c&#233;lulas vasculares, ofrece propiedades de viscoelasticidad y resistencia a la pared del vaso. La ME C tambi&#233;n regula la formaci&#243;n del nuevo brote vascular. Cuando las c&#233;lulas endoteliales migran para formar nuevos brotes vasculares, la matriz no solo se rompe proteol&#237;ticamente, sino que tambi&#233;n su composici&#243;n se altera. Las proteinasas exponen nuevos ep&#237;topos en las prote&#237;nas de la ME C (por ejemplo, el col&#225;geno IV, o alteran su estructura (mon&#243;meras de col&#225;geno fibrilar), lo que conlleva a la migraci&#243;n de las CE y CML <sup>34</sup>. Adem&#225;s de eso, la fibronectina, fibrina y otros componentes de la matriz suministran un mosaico de sustentaci&#243;n para el apoyo y las orientaciones de las CE. </p>
      <p>Las integrinas son receptores de superficie celular espec&#237;ficos de laMECque , por transmisi&#243;n de informaciones bidireccionales entre el exterior y el interior de las c&#233;lulas vasculares, ayudan a construir nuevos brotes vasculares de manera coordinada. Las integrinas a5p3 y a5p5 han venido siendo, desde hace ya mucho tiempo, consideradas un regulador positivo de la angiog&#233;nesis, porque sus antagonistas farmacol&#243;gicos suprimen la angiog&#233;nesis patol&#243;gica<sup>43</sup>. </p>
      <p>El factor de crecimiento derivado de las plaquetas (FCDP) - p y de su receptor FCDP-Rp, desempe&#241;a un papel esencial en la estabilizaci&#243;n de los vasos sangu&#237;neos nacientes, reclutando c&#233;lulas mesenquimales FCDP-Rp positivo. La falta de reclutamiento de las CE tienen como resultado un crecimiento neovascular patol&#243;gico, lo que provoca: la alteraci&#243;n de la permeabilidad neovascular, la fragilidad neovascular, el sangramiento, la insuficiencia de perfusi&#243;n e hipoxia en embriones que les falta FCDP-&#946;<sup>44</sup>. En vez de eso, una combinaci&#243;n de FCDP-&#946;y VEGF resultaen la formaci&#243;n de brotes vasculares m&#225;s maduros que una monoterapia con cualquier uno de los factores. Eso es muy importante para el futuro desarrollo de estrategias terap&#233;uticas de la angiog&#233;nesis. </p>
      <p>Otro sistema de se&#241;alizaci&#243;n involucrado en el mantenimiento, crecimiento y estabilizaci&#243;n del brote neovascular naciente, es el receptor TIE-2, que liga las angiopoietinas Ang-1 y Ang-2. A diferencia de la Ang-2, que activa la TIE-2 en algunas c&#233;lulas, pero bloquea el TIE-2 en otras, la Ang-1 activa consistentemente el receptor TIE-2. La Ang-1 a su vez, compacta los brotes neovasculares nacientes, a trav&#233;s de las mol&#233;culas de adhesi&#243;n y genera una interacci&#243;n entre las CE de las paredes como un adhesivo de prote&#237;nas y la contracci&#243;n de pericitos. La actividad angiog&#233;nica de la Ang-2 est&#225; en la sinergia con el VEGF para estimular la angiog&#233;nesis en el coraz&#243;n, pero cuando los signos no son suficientes, causa la muerte de las CE y la regresi&#243;n del brote neovascular naciente. O sea, que los signos de activaci&#243;n TIE-2 deben funcionar como una b&#225;scula de precisi&#243;n<sup>45</sup>. </p>
      <p>
        <bold>2. Fase intermedia: la estabilizaci&#243;n del nuevo brote neovascular inmaduro. </bold>
      </p>
      <p>El brote naciente neovascular se estabiliza a trav&#233;s del reclutamiento de las c&#233;lulas murales y por la generaci&#243;n de una nueva MEC . Por lo menos cuatro v&#237;as moleculares est&#225;n involucradas en la regulaci&#243;n de ese proceso: FCD P y su receptor p (FCDP-R&#946;); esfingosina-1/fosfato-1 (S1P1); factor de diferenciaci&#243;n endotelial (receptor prote&#237;na esfingosina G-1 (EDG1); Ang1 -TIE-2 y el FCT El FCDP-&#946; es segregado por la CE, tal vez como respuesta al VEGF Aunque el FCDP-&#946; est&#233; expresado por las CE y las c&#233;lulas murales, son &#233;sas las responsables durante la fase de maduraci&#243;n de la angiog&#233;nesis. Tambi&#233;n son esenciales para la formaci&#243;n y la estabilizaci&#243;n del brote neovascular, los receptores TIE-1 y TIE-2, y los dos ligadores para TIE-2, como Ang1 y Ang2. Las principales fuentes de Ang1 y Ang2 son respectivamente, las CE parietales y las CE de los &#243;rganos espec&#237;ficos. El Ang1 es conocida por la estabilizaci&#243;n de los brotes vasculares emergentes y por hacerlos resistentes a la fuga entre las conexiones intercelulares. En la ausencia de VEGF, la Ang2 act&#250;a como un antagonista de la Ang1 y desestabiliza el brote neovascular naciente, conllevando, finalmente, a su regresi&#243;n. En presencia de VEGF, Ang2 facilita la angiog&#233;nesis. El FCT-pi es una citoquina multifuncional que genera el ciclo de maduraci&#243;n del brote neovascular en desarrollo por la estimulaci&#243;n de la MEC , al estimular la inducci&#243;n y la diferenciaci&#243;n de las c&#233;lulas mesenquimales en CE murales<sup>46</sup>. </p>
      <p>
        <bold>3. Fase final: maduraci&#243;n vascular de la angiog&#233;nesis fisiol&#243;gica </bold>
      </p>
      <p>Los determinantes moleculares de maduraci&#243;n neovascular pueden ser agrupados en tres categor&#237;as: I) Uni&#243;n de los factores de crecimiento a un tipo de receptor celular, con su efecto correspondiente; II) Regulaci&#243;n molecular de las interacciones celulares; III) Regulaci&#243;n molecular de las interacciones entre las c&#233;lulas endoteliales y la matriz extracelular. </p>
      <p>I) Uni&#243;n de los factores de crecimiento a un tipo de receptor celular, con su correspondiente efecto: </p>
      <p>a) Receptores de CE fltly flkl (VEGF-R1, VEGF-R2): 1) Regulaci&#243;n de las proteasas en la organizaci&#243;n de la MEC ; 2) Generaci&#243;n de la ME C provisional, que permite aumentar la permeabilidad; 3) Regulaci&#243;n del FCDP-&#946;, que recluta las c&#233;lulas para estabilizar la pared del vaso naciente; 4) Supresi&#243;n de la apoptosis en los vasos nacientes; 5) Estabilizaci&#243;n de las CE. </p>
      <p>b) FCDP-R&#946;; Ang1/TIE-2: 1) Promoci&#243;n de proliferaci&#243;n, migraci&#243;n y reclutamiento de las c&#233;lulas murales; 2) Estabilizaci&#243;n de vasos nacientes, lo que facilita las interacciones entre las junciones intercelulares (CE-CE, CE-MEC); 3) Supresi&#243;n de la apoptosis de las CEc. </p>
      <p>c) Ang2/TIE1: induce a la apoptosis de las CE, en ausencia de VEGF </p>
      <p>d) Ang1/TIE1: coordinan la polaridad vascular. </p>
      <p>e) FCT-&#946;VFCT-&#946;RII: </p>
      <p>1) Promueven la producci&#243;n de proteasas y MEC . </p>
      <p>2) Promueven la diferenciaci&#243;n de fibroblastos para miofibroblastos. </p>
      <p>f) FCT-&#946;1/ALK1 regulan la proliferaci&#243;n y la migraci&#243;n de CE. </p>
      <p>g) FCT-&#946;1/ALK5: regulan la maduraci&#243;n de los nuevos vasos. </p>
      <p>h) FCT-&#946;1/ALK1 y la endoglina: promueven la especializaci&#243;n arterial y venosa. </p>
      <p>II) Regulaci&#243;n molecular de las conexiones intercelulares: </p>
      <p>a) V cadherina: forma las uniones entre las CE. </p>
      <p>b) N-cadherina: conecta las c&#233;lulas de la pared celular y las CE. </p>
      <p>c) Conectinas: establece conexiones entre las CE y las CE y c&#233;lulas parietales. </p>
      <p>III) Regulaci&#243;n molecular de las interacciones entre las CE y la MEC: </p>
      <p>a) &#945;5&#946;1, &#945;1&#946;1, &#945;2&#946;1, &#945;v&#946;3, &#945;v&#946;5: supresi&#243;n de la apoptosis de CE. </p>
      <p>b) Proteasas: en su acci&#243;n enzim&#225;tica promueven la producci&#243;n de la MEC, como por ejemplo, la segmentaci&#243;n del col&#225;geno XVIII para endostatina, el plasmin&#243;geno, la angiotensina y proteasas como MMP 2 y PEX. </p>
      <p>c) Proteasas inhibitorias: evitan la degradaci&#243;n proteol&#237;tica de la ME C para estabilizar el vaso. </p>
      <p>Esos datos sustentan de forma consistente, la hip&#243;tesis de que Ang2 y VEG F conllevan a la formaci&#243;n de los brotes neovasculares, mientras que Ang1 est&#225; involucrada en la estabilizaci&#243;n del brote por interacci&#243;n de las CE y de la c&#233;lula mural<sup>46</sup>. </p>
      <p>
        <bold>3.1. Formaci&#243;n del lumen vascular </bold>
      </p>
      <p>Durante el proceso de angiog&#233;nesis, ocurre la migraci&#243;n y la proliferaci&#243;n de CE por aproximadamente 24 horas, per&#237;odo durante el cual las proteasas tienen un papel crucial<sup>46</sup>. La proliferaci&#243;n queda registrada al nivel de las CE y CML<sup>47</sup>. </p>
      <p>El proceso de formaci&#243;n del lumen vascular es una fase coordinada de adhesi&#243;n molecular-celular durante la extensi&#243;n del vaso sangu&#237;neo. Las mol&#233;culas espec&#237;ficas responsables de la extensi&#243;n del vaso no se conocen muy bien<sup>48</sup>. </p>
      <p>El receptor TIE-2 y de CE es necesario para el desarrollo de los vasos sangu&#237;neos, como tambi&#233;n para su mantenimiento y reparaci&#243;n. La Ang fue identificada como un ligador espec&#237;fico para el receptor TIE-2. Como ya se ha dicho, Ang-1 es un agonista de los receptores TIE-2 que promueve la supervivencia de las CE y reduce la permeabilidad vascular<sup>49</sup>. </p>
      <p>En contraposici&#243;n con la Ang-1, la Ang-2 fue inicialmente descrita como un antagonista que bloquea la TIE-2/Ang-1 y que conduce a la activaci&#243;n del TIE-2, lo que resulta en la apoptosis de las CE. En el sistema de se&#241;alizaci&#243;n de las CE para su supervivencia y migraci&#243;n, el TIE-2 es un componente esencial en el desarrollo de la vasculog&#233;nesis embrionaria, como tambi&#233;n de la angiog&#233;nesis en el adulto. Algunos trabajos recientes identificaron una prote&#237;na tirosina fosfatasa beta como una nueva CE-fosfatasa espec&#237;fica que regula la se&#241;alizaci&#243;n Ang1-TIE-2 de las CE. As&#237;, algunas estrategias dirigidas para HPTP-P pueden ser beneficiosas para la se&#241;alizaci&#243;n de la Ang1 y por tanto, mejoran la formaci&#243;n y la maduraci&#243;n de los neovasos en el contexto de la angiog&#233;nesis terap&#233;utica. Adem&#225;s, podemos concluir diciendo que la hipoxia aumenta la expresi&#243;n de H PTP-P y que reduce la fosforilaci&#243;n de la TIE-2, lo que nos da un nuevo horizonte sobre el papel potencial de la angiog&#233;nesis del H PTP-p. La inducci&#243;n de HPTP-P por la hipoxia, puede representar un importante mecanismo regulador de activaci&#243;n del TIE-2 en la angiog&#233;nesis patol&#243;gica<sup>50</sup>. </p>
      <p>Como colof&#243;n, podemos afirmar que las CE tienen un receptor tirosina-quinasa selectiva; el TIE-2 y sus ligadores, la angiopoietina Ang-1 y Ang-2, a su vez, son esenciales para el mantenimiento y la reparaci&#243;n de los vasos sangu&#237;neos. La Ang-1 es un agonista de la activaci&#243;n de los receptores TIE-2. Sin embargo, la Ang-2 es contexto-dependiente, o sea, que puede ser antagonista o agonista. La prote&#237;na tirosina-fosfatasa beta (H PTP-P), desempe&#241;a un papel relevante en la supervivencia de las c&#233;lulas endoteliales, modulando la se&#241;alizaci&#243;n de Ang-1-TIE-2. </p>
      <p>
        <bold>3.2. Permeabilidad neovascular </bold>
      </p>
      <p>El VEG F conlleva a la proliferaci&#243;n y a la migraci&#243;n de las CE en el proceso de la angiog&#233;nesis. Fue inicialmente identificado como factor de permeabilidad vascular (VPF). Muchas evidencias sugieren que la angiog&#233;nesis viene precedida y/o seguida del aumento de la permeabilidad<sup>4</sup>. </p>
      <p>Los mecanismos por los cuales VEGF/VP F aumentan la permeabilidad vascular (PV), contin&#250;an siendo desconocidos. Murohara et al<sup>51</sup> identifican el &#243;xido n&#237;trico (ON) en la regulaci&#243;n de la PV, mientras que Van Der Zee et al<sup>5 2</sup> identificaron, <italic>in vitro, </italic>que el VEGF/VPF estimula la producci&#243;n de ON en el endotelio macrovascular. </p>
      <p>Isner<sup>4</sup> demostr&#243; la acci&#243;n sin&#233;rgica entre ON y las prostaciclinas producida por la interacci&#243;n del VEGF/VP F con su receptor Flk-1/KDR/VEGF-R2 como mediador de la permeabilidad vascular inducida por VEGF/VPF, constituyendo una propiedad &#250;nica del VEGF/VP F entre las citocinas angiog&#233;nicas. Cuando las proteasas fueron evaluadas por su capacidad de aumentar la permeabilidad por el test de Miles, el VEGF fue el &#250;nico que aument&#243; la permeabilidad. Sin embargo, su mecanismo de acci&#243;n no se conoce. El &#243;xido n&#237;trico ha sido usado como un factor regulador de la permeabilidad, dependiendo de su concentraci&#243;n local<sup>4</sup>. </p>
      <p>Existen tres tipos diferentes de permeabilidad vascular: </p>
      <p>1) permeabilidad de la membrana basal vascular (PBV), presente en los tejidos normales; 2) aumento de la permeabilidad vascular producido en respuesta a una &#250;nica y a una breve exposici&#243;n a la VEGF-A o a otros agentes; </p>
      <p>3) aumento cr&#243;nico de la permeabilidad vascular, que caracteriza la angiog&#233;nesis patol&#243;gica. </p>
      <p>Finalmente, observamos que el VEGF-A var&#237;a significativamente en diferentes cepas del rat&#243;n, y que es probable que la respuesta de la permeabilidad, tanto basal como inducida por algunos factores, tambi&#233;n sea diferente en ratones caseros con diferentes estructuras gen&#233;ticas, aunque eso todav&#237;a no haya sido investigado de forma sistem&#225;tica<sup>53</sup>. </p>
      <p>
        <bold>II. Respuestas de las C&#233;lulas Vasculares a la Hipoxia</bold>
      </p>
      <p>La hipoxia conlleva al aumento de la se&#241;alizaci&#243;n a trav&#233;s de la transcripci&#243;n del FIH-1. </p>
      <p>
        <bold>1. C&#233;lulas endoteliales </bold>
      </p>
      <p>Existen dos mecanismos identificados en la hipoxemia que est&#225;n ligados a la angiog&#233;nesis o a su bloqueo: uno, el que genera la proliferaci&#243;n y la supervivencia a trav&#233;s de CE por la activaci&#243;n de los receptores VEG F de se&#241;alizaci&#243;n y expresi&#243;n de eNOS , y otro, el que inicia la apoptosis. Los resultados pueden depender de la gravedad de la hipoxia. La hipoxemia moderada genera, principalmente, la proliferaci&#243;n y la supervivencia mientras que la hipoxemia grave, que se acerca a las condiciones anaer&#243;bicas, puede causar una apoptosis significativa. <italic>In vivo,</italic> la acumulaci&#243;n de FIH proveniente de la apoptosis de CE no ha sido reportado<sup>6</sup>. </p>
      <p>
        <bold>2. C&#233;lulas musculares lisas vasculares </bold>
      </p>
      <p>Tal como ocurre con las c&#233;lulas endoteliales, la hipoxemia grave provoca apoptosis de las CML, mientras que la hipoxemia moderada aumenta su proliferaci&#243;n. Inducida por la hipoxia, la expresi&#243;n de la ciclo-oxigenasa (COX)-2 y FCDP-&#946; es importante para los receptores de CML, que estimulan su proliferaci&#243;n. El mecanismo preciso no se conoce, pero una posibilidad es que el MT1 -MM P act&#250;e como una mol&#233;cula accesoria de la actividad proteol&#237;tica asociada con el receptor FCDP-&#946;<sup>45</sup>. </p>
      <p>
        <bold>3. Macr&#243;fagos </bold>
      </p>
      <p>En respuesta a la hipoxemia tisular, un gran n&#250;mero de monocitos es reclutado de la circulaci&#243;n hacia los tejidos hip&#243;xicos, donde se diferencian en macr&#243;fagos. Varios factores y prote&#237;nas en los tejidos hip&#243;xicos contribuyen para el reclutamiento de los monocitos, a saber: prote&#237;na-1 (MCP-1), FNT-a, FEC-1, factor derivado del estroma (FDE)-1 y VECF-A. Los macr&#243;fagos generan la angiog&#233;nesis al estimular la secreci&#243;n de metaloproteinasas de la matriz (MMP), y una variedad de factores angiog&#233;nicos, tales como VECF-A, FCF, interleucina-2 y factor de necrosis tumoral. Adem&#225;s, los macr&#243;fagos tambi&#233;n segregan un corto p&#233;ptido de 39 residuos de amino&#225;cidos (PR39), que f&#225;cilmente pueden atravesar la membrana plasm&#225;tica, entrar en las c&#233;lulas e inhibir la degradaci&#243;n del FIH-a. Esa funci&#243;n del PR39 puede mejorar la capacidad de las c&#233;lulas residentes de los tejidos hip&#243;xicos de segregar factores angiog&#233;nicos, debido al aumento de la concentraci&#243;n local de FIH-1 <sup>6</sup>. </p>
      <p>Finalmente, tambi&#233;n los macr&#243;fagos responden a la hipoxemia a trav&#233;s de la producci&#243;n de una prote&#237;na reguladora de ox&#237;geno (PRO), por el ret&#237;culo endoplasm&#225;tico, que genera la secreci&#243;n de VECF-A por el mismo ret&#237;culo endoplasm&#225;tico<sup>6</sup>. </p>
      <p>
        <bold>Conclusi&#243;n </bold>
      </p>
      <p>De manera general, la angiog&#233;nesis coronaria en los adultos es fundamentalmente, una respuesta potente paracrinade la red capilar preexistente en condiciones fisiopatol&#243;gicas de isquemia y/o de inflamaci&#243;n. La investigaci&#243;n b&#225;sica y el entendimiento de los mecanismos son necesarios para darle fundamento a las grandes lagunas que tenemos en el conocimiento y posibilitar la ejecuci&#243;n de efectivas estrategias en el campo de la terapia angiog&#233;nica coronaria. </p>
      <p>
        <bold>Potencial Conflicto de Intereses </bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes. </p>
      <p>
        <bold>Fuentes de Financiaci&#243;n </bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas. </p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica </bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Gabriel Lorier, por IC/FUC. </p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical Update</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Coronary angiogenesis as an endogenous response to myocardial ischemia in adults</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>The process of angiogenesis involves a complex sequence of stimuli and integrated responses, such as stimulation of endothelial cells (ECs) for their proliferation and migration, stimulation of the extracellular matrix (ECM) for the attraction of pericytes and macrophages, stimulation of smooth muscle cells for their proliferation and migration, and formation of new vascular structures. Angiogenesis is mainly an adaptive response to tissue hypoxia and depends on the accumulation of the hypoxia-inducible factor (HIF-1&#945;) in the ischemic myocardial area, which increases the transcription of the vascular endothelial growth factor (VEGF) and its receptors VEGF-R by the ECs undergoing ischemia. Those steps involve enzymatic mechanisms and plasminogen activator proteases, metalloproteinases (MMP) of the ECM, and kinases that cause proteolytic molecular degradation of the ECM and activation and release of growth factors, such as: basic fibroblast growth factor (bFGF), VEGF, and insulin growth factor-1 (IGF-1). In the intermediate phase, stabilization of the immature neovascular sprout occurs. The final phase is characterized by vascular maturation of the physiological angiogenesis. In conclusion, coronary angiogenesis in adults is fundamentally a paracrine response of the preexisting capillary network under pathophysiological condition of ischemia and inflammation.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Myocardial ischemia</kwd>
        <kwd>neovascularization</kwd>
        <kwd>physiologic</kwd>
        <kwd>endothelial cells</kwd>
        <kwd>adult</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>CLINICAL UPDATE</bold>
      </p>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>Coronary angiogenesis as an endogenous response to myocardial ischemia in adults</bold>
          </label>
          <p>
            <bold>Gabriel Lorier<sup>I</sup>; Cristina Touri&#241;o<sup>I</sup>; Renato A. K. Kalil<sup>II,III</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Universidad de La Republica, Montevideo, Uruguay (UDELAR); Porto Alegre, Rio Grande do Sul, Brasil</p>
      <p><sup>II</sup>Instituto de Cardiologia do Rio Grande do Sul - Funda&#231;&#227;o Universit&#225;ria de Cardiologia - (IC/FUC); Porto Alegre, Rio Grande do Sul, Brasil </p>
      <p><sup>III</sup>Universidade Federal de Ci&#234;ncias da Sa&#250;de de Porto Alegre - (UFCSPA), Porto Alegre, Rio Grande do Sul, Brasil</p>
      <p>Mailing adress</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>The process of angiogenesis involves a complex sequence of stimuli and integrated responses, such as stimulation of endothelial cells (ECs) for their proliferation and migration, stimulation of the extracellular matrix (ECM) for the attraction of pericytes and macrophages, stimulation of smooth muscle cells for their proliferation and migration, and formation of new vascular structures.</p>
      <p> Angiogenesis is mainly an adaptive response to tissue hypoxia and depends on the accumulation of the hypoxia-inducible factor (HIF-1&#945;) in the ischemic myocardial area, which increases the transcription of the vascular endothelial growth factor (VEGF) and its receptors VEGF-R by the ECs undergoing ischemia.</p>
      <p> Those steps involve enzymatic mechanisms and plasminogen activator proteases, metalloproteinases (MMP) of the ECM, and kinases that cause proteolytic molecular degradation of the ECM and activation and release of growth factors, such as: basic fibroblast growth factor (bFGF), VEGF, and insulin growth factor-1 (IGF-1). In the intermediate phase, stabilization of the immature neovascular sprout occurs. The final phase is characterized by vascular maturation of the physiological angiogenesis.</p>
      <p> In conclusion, coronary angiogenesis in adults is fundamentally a paracrine response of the preexisting capillary network under pathophysiological condition of ischemia and inflammation.</p>
      <p><bold>Keywords:</bold> Myocardial ischemia, neovascularization, physiologic, endothelial cells, adult.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>This review article approaches endogenous myocardial angiogenesis in the adult considering a unified view of several molecular mechanisms. Such view is based on the "dynamic" interpretation of Folkman's definition: "Angiogenesis is the generation and expansion of blood vessels from a preexisting vascular network under endogenous or exogenous stimuli"<sup>1</sup>. In the adult, angiogenesis is mainly an adaptive response to tissue hypoxia and occurs in a wide variety of situations, ranging from embryonic development to tumor growth<sup>2</sup>. </p>
      <p>Mediating the cascade of cell and molecular events is the activation of the hypoxia-inducible factor (HIF-1), which increases the transcription of vascular endothelial growth factors (VEGF) and their receptors (VEGF-R) by endothelial cells (ECs) undergoing ischemia<sup>3</sup>. </p>
      <p>The preexisting capillary network is believed to be the common site of beginning in the development and generation of new capillaries, mediated by different signal systems that trigger the production of growth factors and that induce the proliferation of endothelial cells. Folkman's definition of angiogenesis is based on solid anatomical and morphometric elements.</p>
      <p>The normal capillary/myocardial fiber ratio in the adult heart is 1:1, meaning one capillary to one myocardial fiber. The maximum diameter of new vessels identified in the angiogenesis process is 200-&#181;m<sup>4</sup>. If there is no epicardial coronary circulation to feed that collateral circulation with adequate blood flow, gradual regression of the angiogenesis process is likely to occur. Myocardial fibers have diameters and lengths ranging from 10 to 25 &#181;m and 50 to 100 &#181;m, respectively, and uniform capillary distribution in the left ventricular wall from 3,000 to 4,000/cm<sup>2 5</sup>. </p>
      <p>Thus, that definition has strong morphometric support, meaning that, in the normal adult heart at rest, a source of nutrients has to exist to maintain cell life. In other words, circulating endothelial progenitor cells (cEPCs) require preexisting coronary circulation to get to the site where myocardial ischemia occurs.</p>
      <p>Analyzing the second component of Folkman's definition, "[...] under endogenous or exogenous stimuli...", it clearly encompassed the two major mechanisms of the angiogenesis process: the endogenous, which comprises the physiological and pathological processes; and the exogenous, which is the cardiovascular angiogenic therapy as an exogenous angiogenesis-inducing form. This review was aimed at assessing the mechanisms of endogenous angiogenesis in physiological processes.</p>
      <p>
        <bold>I. Regulation Phases of the Endogenous Myocardial-Angiogenesis-Inducing Mechanisms in the Adult:</bold>
      </p>
      <p>
        <bold>1. Initial phase: myocardial ischemia as the initial stimulus</bold>
      </p>
      <p>Angiogenesis is mainly an adaptive response to tissue hypoxia and depends on the accumulation of HIF-1&#945;, which, under tissue hypoxia conditions, activates the expression of growth factors and initiates the process of angiogenesis in the ischemic zone from the preexisting coronary network<sup>6</sup>. In addition, the attraction and recruitment of cEPCs and macrophages activate, in the paracrine form, angiogenesis in the area<sup>7</sup>. The VEGF-A expression indicates recruitment of myeloid progenitors in the ischemic myocardium, while the perivascular cells of angiogenesis are mediated by stromal-cell-derived factors (SDF)-1 (<xref ref-type="fig" rid="en_a19fig01m-body3">Figure 1</xref>)<sup>8</sup>. </p>
      <p content-type="asset">
        <fig id="en_a19fig01m-body3">
          <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf01-en.jpg"/></fig>
      </p>
      <p>In ischemic heart disease, both HIF-1&#945; and VEGF-A are present in the atherosclerotic plaque, suggesting that HIF, through angiogenic signaling, is directly involved in the atherosclerotic plaque growth<sup>9</sup>. </p>
      <p>Severe myocardial ischemia leads to accumulation of HIF-1 and the expression of factors that stimulate angiogenic sprouts in the proximities of blood vessels in the ischemic myocardium. It is worth noting that severe and persistent ischemia causes apoptosis of the ECs and myocardial fibers. In addition, myeloid and endothelial bone-marrow-derived progenitors are also recruited to actively support angiogenesis<sup>10</sup>. </p>
      <p>In the myocardium, HIF-1&#945; is clearly important for angiogenesis. However, little is known about HIF-2&#945;. Cardiomyocytes deprived from specific HIF-1&#945; led to a reduction in vascularization, alterations in the energetic metabolism, and abnormality in the contractile function. On the other hand, overexpression of the HIF-1&#945;/VP16 fusion protein (fusion protein containing HIF-1&#945; and herpes virus VP16 sequences) could promote angiogenesis and reduce the size of the infarction in a rat experimental model. Similarly to that which occurs in other hypoxic tissues, HIF-1&#945; is essential to increase the concentration of EC precursors in the bone marrow. Even a partial deficiency of HIF-1&#945;, due to aging, is associated with a significant reduction in the concentration of those cells and with poor vascularization in the ischemic muscle<sup>11</sup>. </p>
      <p>Hypoxemia also regulates the VEGF production and expression, because of the increase in HIF-1 transcription and in mRNA region-3-dependent VEGF stability<sup>11</sup>. </p>
      <p>The molecular mechanism starting angiogenesis can be triggered by deprivation of oxygen and nutrients, such as glucose, which regulate gene expression. In addition, hypoxia regulates TIE-2 receptors, modulators of the VEGF activity, leading ECs to proliferate through the mechanisms of sprouting or division. According to the signal pattern of VEGF and TIE-2, angiogenesis can be induced by sprouts or intussusception<sup>12</sup>. An important fact regarding the therapeutic application of VEGF is that ischemia stimulates its expression and that of its receptors<sup>13</sup>. (<xref ref-type="fig" rid="en_a19fig01m-body3">Figure 1</xref>)</p>
      <p>
        <bold>1.1. Mechanism of angiogenesis through the attraction of circulating stem cells during myocardial acute infarction</bold>
      </p>
      <p>During myocardial ischemia, the increase in expression and stabilization of HIF-1 transcription promotes local production and release of SDF-1 and VEGF-A by ischemic ECs<sup>14</sup>. Circulating HIF regulates several genes of angiogenesis, and VEGF induction is probably the most remarkable. HIF increases the local VEGF concentration in up to 30 times in a few minutes. VEGF stimulates physiological and pathological angiogenesis in a strict dose-dependent response<sup>6</sup>. Those mediators can increase the mobilization and recruitment of cEPCs in the ischemic area<sup>15</sup>. </p>
      <p>The increase in the SDF-1 expression is essential to regulate the selective attraction, migration and retention, in the ischemic myocardium, of cEPCs or ECs with the surface chemokine receptor type 4, CXC-R4<sup>16</sup>. This means that the HIF-1 pathway is the unifying mechanism of the angiogenesis signaling system in the context of acute myocardial infarction (<xref ref-type="fig" rid="en_a19fig01m-body3">Figure 1</xref>).</p>
      <p>Those cEPCs, similarly to that which occurs with bone marrow mesenchymal cells and others, are mobilized, attracted and redirected from the peripheral circulation to myocardial ischemic areas<sup>17</sup>. </p>
      <p>There is evidence that SDF-1 along with signal receptor CXC-R4+ play an important role in the recruitment of circulating bone marrow cells in the context of severe myocardial ischemia. That signal is essential for the recruitment of stem cells in the heart. CXC-R4+ is a cell-surface receptor of SDF-1, expressed on cEPCs and on circulating hematopoeitic stem-cells<sup>18</sup>. </p>
      <p>Circulating endothelial progenitor cells play an important role in endothelial vascular wall maintenance, aiding in reendothelialization (physiological change in ECs) and angiogenesis<sup>19</sup>. </p>
      <p>However, endogenous SDF-1 levels decrease after an AMI, returning to normal four to seven days after the AMI<sup>20</sup>. </p>
      <p>Circulating bone marrow-derived mesenchymal cells constitute a bridge to the interior of the ischemic myocardium, expressed by SDF-1, which can be a facilitating signal to the migration of circulating and bone marrow cells<sup>17</sup>. </p>
      <p>Endothelial precursors were believed to exist only during embryonic life. Currently, precursors are known to exist in the bone marrow and peripheral vessels in adults. Some growth factors, such as the granulocyte colony stimulating factor (GCSF), basic fibroblast growth factor (bFGF), and insulin growth factor 1 (IGF-1), stimulate their differentiation and mobilization<sup>21</sup>. Those endothelial cell precursors colonize new areas of angiogenic sprouts in adults, and, in the future, can be therapeutic targets.</p>
      <p>Rehman et al<sup>22</sup> have questioned the origin of those cEPCs and their true incorporation into the wall of growing vessels. Those authors have reported that most cEPCs derive from monocytes/macrophages, with only a small population of CD-34<sup>+</sup> stem cells/hematopoeitic progenitor cells originating from stem cells/angioblasts. Those monocytes/macrophages secret multiple angiogenic growth factors, which promote, with their paracrine stimulation, neovascular growth<sup>22</sup>. </p>
      <p>The concept of cEPCs is very attractive; however, more than one decade after their discovery, specific markers for cEPCs still lack, and the results of the clinical trials are still controversial. A recent study has shown, by use of a proteomic approach, that cells with a cEPC phenotype could be circulating mononuclear cells with the incorporation of platelet microparticles<sup>23</sup>. </p>
      <p>Schmeisser et al<sup>24</sup> have shown that CD-34<sup>+</sup> monocytes can develop <italic>in vitro</italic> an endothelial phenotype and acquire a tubular form, suggesting a potential role of monocytes in angiogenesis<sup>24</sup>. </p>
      <p>Finally, Ziegelhoeffer et al<sup>25</sup> have reported that, in an adult organism, bone marrow-derived stem cells do not promote vascular growth through their incorporation into vascular walls, but rather through multiple paracrine effects of angiogenic cytokines<sup>25</sup>. </p>
      <p>Briefly: angiogenesis is a physiological mechanism organized under strict regulation, with several factors influencing the active process at molecular level, including several soluble polypeptides, such as VEGF, angiopoietin (Ang), FGF, platelet-derived growth factor (PDGF), transforming growth factor &#946; (TGF-&#946;), tumor necrosis factor (TNF)-&#945;, and GCSF<sup>26</sup>. </p>
      <p>
        <bold>1.2. Mechanism of endogenous angiogenesis through resident cardiac stem cell activation </bold>
      </p>
      <p>The true role of the mechanism of endogenous angiogenesis through resident cardiac stem cell activation and of the quantification of its angiogenic effect is uncertain. Resident cardiac stem cells were able to differentiate into cardiomyocytes, endothelial cells, and smooth muscle cells<sup>27</sup>. Those resident cardiac stem cells express receptors for hepatocyte growth factor (HGF) and for IGF-1, which can lead to the recruitment and proliferation of ECs and restore some functions of the ischemically injured heart, similarly to that which occurs with circulating mesenchymal cells, which can secret HGF and IGF-1 in response to injury<sup>28</sup>. </p>
      <p>
        <bold>1.3. Proliferation of endothelial cells as the common final response to myocardial ischemia: generation of the angiogenic vascular sprout</bold>
      </p>
      <p>In adults, that process is mainly due to hypoxemia and mediated by the activation of HIF-1&#945;, that increases the transcription of VEGF and its receptors, VEGFRs<sup>2</sup>. </p>
      <p>The VEGF stimulates physiological and pathological angiogenesis on a strict dose-dependent relation<sup>29</sup>. The VEGF is a protein with the specific characteristic of stimulating the replication of vascular endothelial cells, essential to angiogenesis<sup>30</sup>. The VEGF-A binds to two tyrosine-kinase receptors (RTKs), VEGFR-1 (Flt-1) and VEGFR-2 (KDR, Flk-1). The Flt-1 tyrosine-kinase receptors (VEGFR-1) are the second highest-affinity receptors for VEGF. Although not so specific, Flk-1 receptors do not have an affinity with cells of the inflammatory system, such as monocytes or cancer cells, unlike the Flt-1 receptor. A recent and elegant study of the Leuven University has made an important discovery with therapeutic implications for the future, which is the relative specificity of VEGF-B regarding its angiogenic activity in ischemic myocardial tissue<sup>31</sup>. </p>
      <p>Regarding the mechanism of angiogenesis, because of the vascular growth in the form of a vascular sprout, the following steps could be determined:</p>
      <p>a) initial vasodilation, a process that involves nitric oxide and VEGF<sup>32</sup>; </p>
      <p>b) increased vascular permeability in response to VEGF, such as plasma protein extravasation, which functions as a support for EC migration. The increase in permeability is produced by the formation of organo-vesicular fenestrations and redistribution of platelet endothelial cell adhesion molecules (PECAMs)<sup>33</sup>; </p>
      <p>c) proteolytic degradation of the extracellular matrix (ECM): proteinases expose proteins of the degraded ECM, such as collagen IV and fibrillar collagen monomer, which induce migration of ECs and smooth muscle cells (SMCs)<sup>34</sup>. </p>
      <p>The three steps described involve enzyme mechanisms that include Ang-2, a TIE-2 inhibitor<sup>35</sup>, plasminogen activator proteases, matrix metalloproteinases (MMP), and kinases or heparinase family.</p>
      <p>All proteases influence angiogenesis through proteolytic molecular degradation of the ECM and activation and release of growth factors, such as bFGF, VEGF, and IGF1, sequestered in the ECM (box 8 of <xref ref-type="fig" rid="en_a19fig02m-body3">Figure 2</xref>)<sup>36</sup>. In addition, proteolytic action is also present in the transforming growth factor (TGF) and proteolytic activation of angiogenic chemokines, such as IL-1. During vascular remodeling through sprouting, proteolytic degradation occurs, involving plasminogen activators, such as urokinase plasminogen activator (UPA) and its inhibitor PAI-1, MMPs, and inhibitors of tissue MMPs (TIMPs), heparinases, kinases, tyrosinases, and cadherins<sup>37</sup>. </p>
      <p content-type="asset">
        <fig id="en_a19fig02m-body3">
          <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf02-en.jpg"/></fig>
      </p>
      <p>Analyzing the critical role of the ECM proteolytic degradation in the growth and maintenance of the angiogenic sprout, the time limits of that process should be considered. In addition, the process should be balanced, because insufficient degradation prevents vascular cells from leaving their original positions. On the other hand, excessive degradation hinders the support and orientation for EC migration, and, consequently, also angiogenesis<sup>38</sup>. </p>
      <p>In the angiogenesis process, the ECM proteolytic degradation is followed by fragmentation of the basal membrane, and then by chemotactic migration of the ECs through the basal membrane. That requires cleavage of endothelial intercellular connections. When the ECs migrate to form new sprouts, the ECM undergoes proteolytic degradation and changes in its composition (<xref ref-type="fig" rid="en_a19fig03m-body3">Figure 3</xref>).</p>
      <p content-type="asset">
        <fig id="en_a19fig03m-body3">
          <graphic xlink:href="1678-4170-abc-97-06-e140-00019-gf03-en.jpg"/></fig>
      </p>
      <p>Migration of the ECs occurs 24 hour before the following processes:</p>
      <p>a) proliferation;</p>
      <p>b) adhesion and reestablishment of intracellular contacts;</p>
      <p>c) formation of the vascular lumen;</p>
      <p>d) functional maturation of the endothelium.</p>
      <p>As shown, proteases play a critical role in the angiogenesis process<sup>39</sup>. </p>
      <p>The VEGF stimulation of the tyrosine-kinase membrane receptors of the ECs is expressed through Src genes of the tyrosine-kinase family, such as Src, Fyn, and Yes, which regulate multiple intracellular functions. Each of the Src, Fyn and Yes genes plays a unique role in the VEGF mitogenic signaling system. They contribute to VEGF modulation in cell migration. The Fyn gene plays a unique role in VEGF induction for the formation of the neovascular tube, having a negative regulatory effect on the migration and stabilization of the VEGF-induced neovascular tube. Those results provide direct evidence that the Src, Fyn and Yes genes play an important role in VEGF regulation in EC-mediated events<sup>40</sup>. </p>
      <p>The existence of tubes with pericytes reflects the early beginning of the participation of pericytes in intussusceptive angiogenesis (box 4 of <xref ref-type="fig" rid="en_a19fig02m-body3">Figure 2</xref>). The creation of a functional vascular network requires that emerging vascular sprouts mature and remain functional over time. The association of pericytes and SMC with the recently formed EC sprouts regulates their proliferation, survival, migration, differentiation, vascular branching, blood flow, and vascular permeability. The early participation of the pericytes in the development of the microvasculature has important implications for the therapeutic intervention in several diseases<sup>41</sup>. </p>
      <p>Blood flow, exerting pressure on the new vascular wall, interacts in an integrated and dynamic way with the cytoskeleton and ECM. Continuous blood flow stimulates the proliferation of ECs and regulates VEGF, integrin aVb3, PECAM-1, and VE-cadherin. Shear stress stimulates EC proliferation, and, thus, increases the diameter of the vessel<sup>42</sup>. </p>
      <p>The ECM provides the necessary contacts between the ECs and surrounding tissues, preventing the degeneration of the neovascular sprouts. A matrix of interstitial collagen and elastin between the vascular cells provide viscoelasticity and resistance to the vascular wall. The ECM also regulates the formation of the new vascular sprout. When the ECs migrate to form new vascular sprouts, the matrix is not only proteolytically cleaved, but its composition is altered as well. Proteinases expose new epitopes in the ECM proteins (for example, collagen IV) or alter their structure (fibrillar collagen monomers), leading to migration of ECs and SMCs<sup>34</sup>. In addition, fibronectin, fibrin and other components of the matrix provide support and orientation for ECs.</p>
      <p>Integrins are specific cell surface receptors of the ECM, which, through transmission of bidirectional information between the exterior and interior of the vascular cells, help in constructing new vascular sprouts coordinately. Integrins &#945;5&#946;3 and &#945;5&#946;5 have long been considered a positive regulator of angiogenesis, because their pharmacological antagonists suppress pathological angiogenesis<sup>43</sup>. </p>
      <p>Platelet-derived growth factor-&#946; and its receptor (PDGF-R&#946;) play an essential role in the stabilization of new blood vessels, recruiting PDGF-R&#946;-positive mesenchymal cells. The lack of EC recruitment results in pathological neovascular growth, which causes: neovascular permeability changes; neovascular fragility; bleeding; insufficient perfusion; and hypoxia in embryos lacking PDGF-&#946;<sup>44</sup>. However, a combination of PDGF-&#946; and VEGF results in the formation of more mature vascular sprouts than that obtained with monotherapy with any of the factors. That is extremely important for the future development of therapeutic strategies of angiogenesis.</p>
      <p>Another signaling system involved in the maintenance, growth, and stabilization of the neovascular sprout is the TIE-2 receptor, which binds Ang-1 and Ang-2. Differently from Ang-2, which activates TIE-2 in some cells, but blocks TIE-2 in other cells, Ang-1 consistently activates the TIE-2 receptor. On its turn, Ang-1 compacts the neovascular sprouts through binding molecules and causes the interaction of mural ECs, as a protein adhesive, and the contraction of pericytes. The angiogenic activity of Ang-2 is synergic with VEGF to stimulate cardiac angiogenesis, but when the signals are not sufficient, it causes the death of the ECs and regression of the neovascular sprout. The TIE-2 activation signs should function as a precision scale<sup>45</sup>. </p>
      <p>
        <bold>2. Intermediate phase: stabilization of the immature neovascular sprout </bold>
      </p>
      <p>The neovascular sprout is stabilized through the recruitment of mural cells and generation of a new ECM. At least four molecular pathways are involved in the regulation of that process: PDGF and PDGF-R&#946;; sphingosine-1-phosphate-1 (S1P1); endothelial differentiation factor [sphingosine G-1 protein receptor (EDG1)]; Ang-1-TIE-2; and TGF. The PDGF-&#946; is secreted by the EC, probably in response to VEGF. Although PDGF-&#946; is expressed by ECs and mural cells, the latter are responsible during the maturation phase of angiogenesis. In addition, the TIE-1 and TIE-2 receptors and the two TIE-2 ligands, Ang-1 and Ang-2, are essential for the formation and stabilization of the neovascular sprout. The major sources of Ang-1 and Ang-2 are the mural and specific organ ECs, respectively. Angiopoietin-1 is known due to its ability to stabilize the emerging vascular sprouts and to make them resistant to evasion between intercellular connections. In the absence of VEGF, Ang-2 acts as an Ang-1 antagonist and destabilizes the emerging neovascular sprout, eventually leading to its regression. In the presence of VEGF, Ang-2 facilitates angiogenesis. The TGF-&#946;1 is a multifunctional cytokine that promotes the maturation cycle of the developing neovascular sprout through ECM stimulation, by stimulating the induction and differentiation of mesenchymal cells into mural ECs<sup>46</sup>. </p>
      <p>
        <bold>3. Final phase: vascular maturation of physiological angiogenesis</bold>
      </p>
      <p>The molecular determinants of neovascular maturation can be grouped into three categories: I) growth factor binding to a cell receptor type, and its corresponding effect; II) molecular regulation of cell interactions; III) molecular regulation of the interactions between ECs and ECM.</p>
      <p>I) Growth factor binding to a cell receptor type, and its corresponding effect:</p>
      <p>a) EC receptors Flt-1 and Flk-1 (VEGF-R1, VEGF-R2): 1) Regulation of proteases in the ECM organization; 2) Generation of temporary ECM, which allows permeability increase; 3) Regulation of PDGF-&#946;, which recruits cells to stabilize the emerging vessel wall; 4) Suppression of apoptosis in emerging vessels; 5) Stabilization of ECs.</p>
      <p>b) PDGF-R&#946;; Ang-1/TIE-2: 1) Promotion of proliferation, migration and recruitment of mural cells; 2) Stabilization of emerging vessels, which facilitates the interactions between intercellular junctions (EC-EC, EC-ECM); 3) Suppression of apoptosis of ECs.</p>
      <p>c) Ang-2/TIE-1: induce apoptosis of ECs, in the absence of VEGF.</p>
      <p>d) Ang-1/TIE-1: coordinate vascular polarity.</p>
      <p>e) TGF-&#946;1/TGF-&#946;RII: </p>
      <p>1) Promote the production of proteases and ECM.</p>
      <p>2) Promote the differentiation of fibroblasts into myofibroblasts.</p>
      <p>f) TGF-&#946;1/ALK1: regulate the proliferation and migration of ECs.</p>
      <p>g) TGF-&#946;1/ALK5: regulate the maturation of new vessels.</p>
      <p>h) TGF-&#946;1/ALK1 and endoglin: promote arterial and venous specialization.</p>
      <p>II) Molecular regulation of cell interactions:</p>
      <p>a) V-cadherin: binds ECs.</p>
      <p>b) N-cadherin: connect the cells of the vascular wall to ECs.</p>
      <p>c) Connectins: establish connections between ECs and ECs and mural cells.</p>
      <p>III) Molecular regulation of the interactions between ECs and ECM:</p>
      <p>a) &#945;5&#946;1, &#945;1&#946;1, &#945;2&#946;1, &#945;v&#946;3, &#945;v&#946;5: suppression of EC apoptosis.</p>
      <p>b) Proteases: their enzymatic action promotes the production of the ECM, such as cleavage of the collagen XVIII to endostatin, plasminogen, angiotensin and proteases (for example, MMP2 and PEX).</p>
      <p>c) Inhibitory proteases: prevent the ECM proteolytic cleavage to stabilize the vessel.</p>
      <p>Such data consistently support the hypothesis that Ang-2 and VEGF lead to the formation of neovascular sprouts, while Ang-1 is involved in stabilizing the sprout through the interaction of ECs and mural cells<sup>46</sup>. </p>
      <p>
        <bold>3.1. Formation of the vascular lumen</bold>
      </p>
      <p>During the angiogenesis process, EC migration and proliferation occur for approximately 24 hours, a period during which proteases play a crucial role<sup>46</sup>. Proliferation is recorded at the level of ECs and SMCs<sup>47</sup>. </p>
      <p>The process of the vascular lumen formation is a coordinate phase of molecular-cellular adhesion during blood vessel extension. The specific molecules responsible for vessel extension are not well known<sup>48</sup>. </p>
      <p>The receptor of TIE-2 and EC is necessary for the development of blood vessels, as well as for their maintenance and repair. Angiopoietin was identified as a specific ligand for the TIE-2 receptor. As already cited, Ang-1 is an agonist of TIE-2 receptors that promotes EC survival and reduces vascular permeability<sup>49</sup>. </p>
      <p>Unlike Ang-1, Ang-2 has been initially described as an antagonist that blocks TIE-2/Ang-1 and activates TIE-2, which results in EC apoptosis. In the signaling system of ECs, for their survival and migration, TIE-2 is an essential component for the development of embryonic vasculogenesis, as well as for angiogenesis in the adult. Recent studies have identified protein tyrosine phosphatase beta (HPTP-&#946;) as a new specific EC-phosphatase that regulates the Ang-1-TIE-2 signaling of ECs. Thus, the strategies oriented to HPTP-&#946; can benefit Ang-1 signaling, and, thus, improve the formation and maturation of neovessels in the context of therapeutic angiogenesis. In addition, one can conclude that hypoxia increases HPTP-&#946; expression and decreases TIE-2 phosphorylation, shedding new light on the potential role of HPTP-&#946; on angiogenesis. The induction of HPTP-&#946; due to hypoxia can represent an important regulatory mechanism of TIE-2 activation in pathological angiogenesis<sup>50</sup>. </p>
      <p>Briefly, ECs have a selective tyrosine-kinase receptor; TIE-2 and its ligands, Ang-1 and Ang-2, are essential for the maintenance and repair of blood vessels. Ang-1 is an agonist of the activation of TIE-2 receptors. However, Ang-2 is context-dependent, which means, it can be either antagonist or agonist. In the survival of ECs, HPTP-&#946; plays a relevant role modulating Ang-1-TIE-2 signaling.</p>
      <p>
        <bold>3.2. Neovascular permeability</bold>
      </p>
      <p>In the angiogenesis process, VEGF leads to proliferation and migration of ECs. It was initially identified as a vascular permeability factor (VPF). There is plenty of evidence suggesting that angiogenesis is preceded and/or accompanied by increased permeability<sup>4</sup>. </p>
      <p>The mechanisms by which VEGF/VPF increases vascular permeability (VP) remain unknown. Murohara et al<sup>51</sup> have identified nitric oxide (NO) in VP regulation, while van der Zee et al<sup>52</sup> have identified, <italic>in vitro</italic>, that VEGF/VPF stimulates NO production in the macrovascular endothelium. </p>
      <p>Isner<sup>4</sup> has shown the synergic action between NO and prostacyclins produced by the interaction of VEGF/VPF with its receptor Flk-1/KDR/VEGF-R2 as a mediator of the VEGF/VPF-induced vascular permeability, constituting a unique property of VEGF/VPF among the angiogenic cytokines. When the proteases were assessed based on their capacity to increase permeability by the Miles test, VEGF was the only to increase permeability - the mechanism of action, however, is unknown. Nitric oxide has been implicated as a permeability regulator factor, depending on its local concentration<sup>4</sup>. </p>
      <p>There are three different types of vascular permeability:</p>
      <p>1) vascular basal membrane permeability (VBMP), present in normal tissues;</p>
      <p>2) increased vascular permeability in response to a single and brief exposure to VEGF-A or other agents;</p>
      <p>3) chronic increase in vascular permeability, which characterizes pathological angiogenesis.</p>
      <p>Finally, VEGF-A varies significantly in different rat strains, and the permeability response, both basal and induced by some factors, is likely to differ in mice with different genetic structures, although systematic investigation still lacks<sup>53</sup>. </p>
      <p>
        <bold>II. Responses of Vascular Cells to Hypoxia</bold>
      </p>
      <p>Hypoxia leads to increased signaling through HIF-1transcription.</p>
      <p>
        <bold>1. Endothelial cells</bold>
      </p>
      <p>There are two mechanisms identified in hypoxemia that are linked to angiogenesis or its block: one that promotes proliferation and survival of ECs through the activation of VEGF receptors and eNOS signaling and expression; and another that initiates apoptosis. The results depend on the severity of hypoxia. Moderate hypoxemia mainly promotes proliferation and survival, while severe hypoxemia, close to anaerobic conditions, can cause significant apoptosis. <italic>In vivo</italic>, the accumulation of HIF resulting from EC apoptosis has not been reported<sup>6</sup>. </p>
      <p>
        <bold>2) Vascular smooth muscle cells </bold>
      </p>
      <p>Similarly to that which occurs with ECs, severe hypoxemia causes apoptosis of SMCs, while moderate hypoxemia increases their proliferation. Induced by hypoxia, the expression of cyclooxygenase (COX)-2 and PDGF-&#946; is important for the receptors of SMCs that stimulate their proliferation. The precise mechanism is unknown, but membrane-type matrix metalloproteinase (MT1-MMP) might act as an accessory molecule of the proteolytic activity associated with the PDGF-&#946; receptor<sup>45</sup>. </p>
      <p>
        <bold>3) Macrophages</bold>
      </p>
      <p>In response to tissue hypoxemia, a large number of monocytes are recruited from the circulation to hypoxic tissues, where they differentiate into macrophages. Several factors and proteins in hypoxic tissues contribute to the recruitment of monocytes as follows: monocyte chemotactic protein-1 (MCP-1); TNF-a; colony stimulating factor-1 (CSF-1); SDF-1, and VEGF-A. Macrophages promote angiogenesis by stimulating the secretion of MMPs and several angiogenic factors, such as VEGF-A, FGF, interleukin-2, and TNF. In addition, macrophages also secret a short peptide with 39 amino acid residues (PR39), which can easily cross the plasma membrane, enter the cells, and inhibit HIF-&#945; cleavage. That PR39 function can improve the capacity of the resident cells of hypoxic tissue to secret angiogenic factors, because of the increase in the local HIF-1 concentration<sup>6</sup>. </p>
      <p>Finally, macrophages respond to hypoxemia through the production of an oxygen-regulated protein (ORP) by the endoplasmic reticulum and the secretion of VEGF-A by the same endoplasmic reticulum<sup>6</sup>. </p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>In general, coronary angiogenesis in adults is fundamentally a potent paracrine response of the preexisting capillary network to pathophysiological conditions of ischemia and/or inflammation. Basic research and understanding the mechanisms are required to fill in the knowledge gaps and enable the establishment of effective strategies in the field of coronary angiogenic therapy. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Doctoral submitted by Gabriel Lorier, from IC/FUC.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
